1 | (-)-trans-delta-9-Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
2 | (IM) AVONEX® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
3 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 |
4 | 0,5 mg Fingolimod | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
5 | 0.25 mg RPC1063 | - | - | - | - | 3件: 13 13, 96, 97 |
6 | 0.25mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
7 | 0.5 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
8 | 0.5mg RPC1063 | - | - | - | - | 1件: 13 13 |
9 | 032166011 | - | - | - | - | 1件: 13 13 |
10 | 033283045 | - | - | - | - | 1件: 13 13 |
11 | 034091165 | - | - | - | - | 1件: 13 13 |
12 | 035418060 | - | - | - | - | 1件: 13 13 |
13 | 1 - Andrographis paniculata p/st extract | - | - | - | - | 1件: 13 13 |
14 | 1 mg RPC1063 | - | - | - | - | 2件: 13 13, 97 |
15 | 1% Steroid Cream | - | - | - | - | 1件: 13 13 |
16 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 |
17 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 |
18 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
19 | 10000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
20 | 11C-ACETATE | 2件: Acetate Acetate, Acetic acid C-11 | - | - | - | 3件: 13 13, 86, 88 |
21 | 11C-BMS-986196 | - | - | - | - | 1件: 13 13 |
22 | 11C-MCI | - | - | - | - | 1件: 13 13 |
23 | 11C-PBR28 | - | - | - | - | 2件: 6 6, 13 |
24 | 11C-PiB | - | - | - | - | 2件: 6 6, 13 |
25 | 11C]-PK-11195 | - | - | - | - | 1件: 13 13 |
26 | 11C]flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 |
27 | 13-PCV Booster | - | - | - | - | 1件: 13 13 |
28 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | 1件: 13 13 |
29 | 1393641-34-3 | - | - | - | - | 1件: 13 13 |
30 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 |
31 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
32 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 |
33 | 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 13件: 5 5, 6, 7, 8, 13, 41, 46, 53, 84, 85, 96, 127, 300 |
34 | 18F-PM-PBB3 | - | - | - | - | 1件: 13 13 |
35 | 18F]DPA-714 | - | - | - | - | 2件: 13 13, 127 |
36 | 19 nor vitamin d | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
37 | 2 - Excipients | - | - | - | - | 1件: 13 13 |
38 | 2 mA Transcranial Direct Current Stimulation | - | - | - | - | 1件: 13 13 |
39 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | - | - | - | - | 1件: 13 13 |
40 | 2-CdA | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
41 | 2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
42 | 2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
43 | 2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
44 | 2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
45 | 2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
46 | 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
47 | 2-chloro-2'-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
48 | 2-chloro-2'-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
49 | 2-chloro-2'-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
50 | 2-chloro-2'-deoxyadenosine, 2CdA | - | - | - | - | 1件: 13 13 |
51 | 2-chloro-2?-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
52 | 2-chloro-2?-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
53 | 2-chloro-2’-deoxy-beta-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
54 | 2-chloro-2’-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
55 | 2-chloro-2’-deoxy-ß-D-adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
56 | 2-chloro-2’-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 17件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
57 | 2-chloro-2’-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
58 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
59 | 20 mg GA | - | - | - | - | 1件: 13 13 |
60 | 20 mg MitoQ | - | - | - | - | 1件: 13 13 |
61 | 200106 or EMD 28162 | - | - | - | - | 1件: 13 13 |
62 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 |
63 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
64 | 23-PPV | - | - | - | - | 1件: 13 13 |
65 | 23-valent pneumococcal polysaccharide vaccine | - | - | - | - | 3件: 13 13, 46, 53 |
66 | 23-valent pneumococcal polysaccharide vaccine (23-PPV) | - | - | - | - | 1件: 13 13 |
67 | 25OH-Vitamin D | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
68 | 2B3-201 | - | - | - | - | 1件: 13 13 |
69 | 3 mg Melatonin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
70 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 |
71 | 4 mA Transcranial Direct Current Stimulation | - | - | - | - | 1件: 13 13 |
72 | 4-Aminopyridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 13 |
73 | 4-AP | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
74 | 4.5 mg Naltrexone | 1件: Naltrexone Naltrexone | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
75 | 40 mg GA | - | - | - | - | 2件: 2 2, 13 |
76 | 40 mg glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 2件: 2 2, 13 |
77 | 40 mg Glatiramer acetato | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
78 | 40mg of MitoQ | - | - | - | - | 1件: 13 13 |
79 | 5 mg Melatonin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
80 | 5000IU vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
81 | 52069.00.01 | - | - | - | - | 1件: 13 13 |
82 | 9060X | - | - | - | - | 2件: 13 13, 149 |
83 | 95% Pure ECGC capsules 200mg | - | - | - | - | 1件: 13 13 |
84 | [123I]CLINDE | - | - | - | - | 2件: 6 6, 13 |
85 | [18F] PBR06 | - | - | - | - | 2件: 6 6, 13 |
86 | [18F]-FEPPA | - | - | - | - | 2件: 6 6, 13 |
87 | [18F]Florbetapir PET imaging | - | - | - | - | 1件: 13 13 |
88 | [C-11]Methylreboxetine | - | - | - | - | 1件: 13 13 |
89 | [C-11]PBR28 | - | - | - | - | 1件: 13 13 |
90 | [C11]PK-1195 PET scan | - | - | - | - | 1件: 13 13 |
91 | [F-18]PBR06 | - | - | - | - | 2件: 13 13, 17 |
92 | [F-18]SDM-8 | - | - | - | - | 1件: 13 13 |
93 | [Zr-89]Oxine-labeled leukocytes PET/MR | 1件: Oxyquinoline Oxyquinoline | 1件: D05321
D05321
| - | - | 1件: 13 13 |
94 | A4I Antagonist | - | - | - | - | 1件: 13 13 |
95 | AB1010 | - | - | - | - | 6件: 2 2, 5, 6, 13, 46, 96 |
96 | Abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
97 | Abobotulinumtoxin A | - | - | - | - | 1件: 13 13 |
98 | ABR-215062 | - | - | - | - | 1件: 13 13 |
99 | ABR-215062 sodium salt | - | - | - | - | 2件: 13 13, 96 |
100 | ABT-555 | - | - | - | - | 1件: 13 13 |
101 | ABT-874/Human monoclonal antibody against IL-12 | - | - | - | - | 1件: 13 13 |
102 | ABX-1431 | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 |
103 | ABX-1431 HCl | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 |
104 | Acetaminophen | 1件: Acetaminophen Acetaminophen | 1件: D00217
D00217
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 16件: 11 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337 |
105 | Acetaminophen Tab 650mg | 1件: Acetaminophen Acetaminophen | 1件: D00217
D00217
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
106 | Acetate | 1件: Acetate Acetate | - | - | - | 43件: 1 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 67, 70, 71, 73, 75, 76, 78, 79, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 227, 235, 265, 288, 298, 299 |
107 | Acetazolamide | 1件: Acetazolamide Acetazolamide | 2件: D00218
D00218
,
D01196
| 13件: CA1 CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 💬 | 7件: Bile secretion Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation 💬 | 6件: 13 13, 90, 115, 155, 225, 230 |
108 | Acetylcysteine | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 20件: 6 6, 13, 19, 20, 34, 49, 51, 53, 58, 85, 90, 94, 111, 164, 193, 233, 296, 298, 299, 337 |
109 | ACETYLSALICYLIC ACID | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 4件: 13 13, 46, 51, 210 |
110 | Acetylsalicylic acid at 1st visit, | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
111 | Aciclovir | 1件: Acyclovir Acyclovir | 1件: D00222
D00222
| - | - | 3件: 13 13, 28, 60 |
112 | Aclasta | - | - | - | - | 3件: 13 13, 271, 274 |
113 | Aclasta 5 mg Infusionslösung | 1件: Zoledronic acid Zoledronic acid | 4件: D01968
D01968
,
D06378
,
D06379
,
D08689
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
114 | Aclasta 5mg solution for infusion | - | - | - | - | 1件: 13 13 |
115 | ACT | - | - | - | - | 1件: 13 13 |
116 | ACT-1 | - | - | - | - | 1件: 13 13 |
117 | ACT-128800 | - | - | - | - | 1件: 13 13 |
118 | ACT-128800 Dose 1 | - | - | - | - | 1件: 13 13 |
119 | ACT-128800 Dose 2 | - | - | - | - | 1件: 13 13 |
120 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 |
121 | ACTH | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 5件: 13 13, 66, 145, 193, 222 |
122 | Acthar | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 9件: 2 2, 13, 14, 46, 49, 50, 66, 84, 222 |
123 | Acthar Gel | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 6件: 13 13, 46, 49, 50, 84, 222 |
124 | ACTHAR Gel (ACTH) | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
125 | Active Comparator receiving Extavia® | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
126 | Active Control | - | - | - | - | 1件: 13 13 |
127 | ACTOS (Pioglitazone) | 1件: Pioglitazone Pioglitazone | 2件: D00945
D00945
,
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 13 13 |
128 | Acyclovir | 1件: Acyclovir Acyclovir | 1件: D00222
D00222
| - | - | 2件: 13 13, 28 |
129 | Ad26.COV2.S | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
130 | Adderall XR | - | - | - | - | 1件: 13 13 |
131 | Adderall XR 10 mg | - | - | - | - | 1件: 13 13 |
132 | Adderall XR 5mg | - | - | - | - | 1件: 13 13 |
133 | Adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 13 13, 58, 65 |
134 | Adrenocorticotropic Hormone | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 3件: 13 13, 50, 84 |
135 | Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®) | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
136 | ADS-5102 | - | - | - | - | 2件: 6 6, 13 |
137 | ADS-5102, 137 mg | - | - | - | - | 1件: 13 13 |
138 | ADS-5102, 274 mg | - | - | - | - | 1件: 13 13 |
139 | AERT, (R)-Baclofen | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
140 | AGEE cream | - | - | - | - | 1件: 13 13 |
141 | AHSC | - | - | - | - | 1件: 13 13 |
142 | AIMSPRO | - | - | - | - | 2件: 13 13, 51 |
143 | AIN | - | - | - | - | 1件: 13 13 |
144 | AIN457 | - | - | - | - | 8件: 13 13, 37, 41, 46, 56, 96, 107, 271 |
145 | Air | - | - | - | - | 8件: 3 3, 13, 51, 58, 85, 97, 193, 299 |
146 | AL | - | - | - | - | 10件: 5 5, 7, 13, 28, 51, 67, 86, 97, 114, 127 |
147 | Alanine | 1件: Alanine Alanine | 1件: D00012
D00012
| - | - | 5件: 6 6, 13, 251, 298, 299 |
148 | Albumin (Human) 25%, United States Pharmacopeia (USP) | - | - | - | - | 2件: 13 13, 14 |
149 | Albuterol | 1件: Salbutamol Salbutamol | 1件: D02147
D02147
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 12 12, 13, 86, 89, 113, 231, 256, 299 |
150 | Alcohol | 1件: Ethanol Ethanol | 4件: D00068
D00068
,
D02798
,
D04855
,
D06542
| - | - | 4件: 13 13, 58, 279, 298 |
151 | Alcohol Wipes vs. No Alcohol Wipes | 1件: Ethanol Ethanol | 4件: D00068
D00068
,
D02798
,
D04855
,
D06542
| - | - | 1件: 13 13 |
152 | ALEMTUZUMAB | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 17件: 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 |
153 | Alemtuzumab (GZ402673) | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
154 | Alemtuzumab 12 mg | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
155 | Alemtuzumab 24 mg | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
156 | Alemtuzumab GZ402673 | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
157 | Alemtuzumab immunotherapy | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
158 | Alemtuzumab Injection | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
159 | Alemtuzumab Injection [Lemtrada] | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
160 | Alfuzosin | 1件: Alfuzosin Alfuzosin | 2件: D01692
D01692
,
D07124
| 1件: ADRA1A ADRA1A 💬 | 7件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
161 | ALKS 8700 | - | - | - | - | 1件: 13 13 |
162 | ALKS 8700 Delayed Release (DR) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 |
163 | ALKS 8700 Delayed Release (DR) Capsule | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 |
164 | All patients in the study will be treated with ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
165 | Allogeneic fecal microbiota | - | - | - | - | 1件: 13 13 |
166 | Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells | - | - | - | - | 1件: 13 13 |
167 | AlloRx | - | - | - | - | 8件: 2 2, 6, 13, 46, 51, 85, 90, 226 |
168 | Alpha Lipoic Acid | 1件: Lipoic acid Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 1件: 13 13 |
169 | ALPHA-LIPOIC ACID | 1件: Lipoic acid Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 2件: 2 2, 13 |
170 | Alpha1-antitrypsin | - | - | - | - | 1件: 13 13 |
171 | ALTRI FARMACI DEL SISTEMA NERVOSO | - | - | - | - | 1件: 13 13 |
172 | ALXN1210 | - | - | - | - | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
173 | AMANTADINE | 1件: Amantadine Amantadine | 2件: D00777
D00777
,
D07441
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 4件: 6 6, 8, 13, 127 |
174 | American Ginseng | 2件: Ginseng Ginseng, Panax quinquefolius whole | 1件: D06772
D06772
| - | - | 1件: 13 13 |
175 | American ginseng extract HT-1001 | 2件: Ginseng Ginseng, Panax quinquefolius whole | 1件: D06772
D06772
| - | - | 1件: 13 13 |
176 | Amiloride | 1件: Amiloride Amiloride | 2件: D00649
D00649
,
D07447
| 3件: SCNN1A SCNN1A, SCNN1B, SCNN1G 💬 | 2件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Taste transduction 💬 | 4件: 13 13, 67, 225, 299 |
177 | Amiloride Hydrochloride | 1件: Amiloride Amiloride | 2件: D00649
D00649
,
D07447
| 3件: SCNN1A SCNN1A, SCNN1B, SCNN1G 💬 | 2件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Taste transduction 💬 | 1件: 13 13 |
178 | AMILORIDE HYDROCHLORIDE, 2 H2O | 1件: Amiloride Amiloride | 2件: D00649
D00649
,
D07447
| 3件: SCNN1A SCNN1A, SCNN1B, SCNN1G 💬 | 2件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption, Taste transduction 💬 | 1件: 13 13 |
179 | Amilostad | - | - | - | - | 1件: 13 13 |
180 | Amilostad HCT | - | - | - | - | 1件: 13 13 |
181 | Amilostad HCT tablets | - | - | - | - | 1件: 13 13 |
182 | Ampyra | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 6 6, 13 |
183 | Amyvid | 1件: Florbetapir (18F) Florbetapir (18F) | - | - | - | 2件: 13 13, 127 |
184 | Amyvid radiopharmaceutical | 1件: Florbetapir (18F) Florbetapir (18F) | - | - | - | 1件: 13 13 |
185 | AN100226 | - | - | - | - | 2件: 13 13, 96 |
186 | AN100226, BG00002 | - | - | - | - | 1件: 13 13 |
187 | Anakinra | 1件: Anakinra Anakinra | 1件: D02934
D02934
| 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 |
188 | AndroGel 1 % Topical Gel | - | - | - | - | 1件: 13 13 |
189 | Androgel 10 grams of gel containing 100 mg of testosterone | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
190 | Andrographolides | - | - | - | - | 1件: 13 13 |
191 | Anesthetic Topical Adhesive Synera | - | - | - | - | 1件: 13 13 |
192 | ANK-700 | - | - | - | - | 1件: 13 13 |
193 | Anti LP40 antibody, subclass IgG4 LA294 | - | - | - | - | 2件: 13 13, 46 |
194 | Anti-CD25 Humanized Monoclonal Antibody | - | - | - | - | 1件: 13 13 |
195 | Anti-CD52 monoclonal antibody | - | - | - | - | 1件: 13 13 |
196 | Anti-IL-12 | - | - | - | - | 2件: 13 13, 96 |
197 | Anti-Thymocyte Globulin | - | - | - | - | 18件: 11 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
198 | Anticholinergic medication | - | - | - | - | 1件: 13 13 |
199 | Anticuerpo monoclonal anti-LINGO-1 humano | - | - | - | - | 1件: 13 13 |
200 | Antihistamine | - | - | - | - | 2件: 13 13, 46 |
201 | Antimycotic | - | - | - | - | 1件: 13 13 |
202 | Antithymocyte | - | - | - | - | 1件: 13 13 |
203 | ANTITHYMOCYTE IMMUNOGLOBULIN | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 2件: 13 13, 96 |
204 | Antithymocyte immunoglobulin (rabbit) | 2件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Rabbit | - | - | - | 2件: 13 13, 96 |
205 | Anxiety/depression and work and activities | - | - | - | - | 1件: 13 13 |
206 | AP | - | - | - | - | 4件: 2 2, 6, 13, 299 |
207 | Apitox - pure honeybee toxin | - | - | - | - | 1件: 13 13 |
208 | Arbaclofen | 1件: Arbaclofen Arbaclofen | 1件: D09791
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 2件: 13 13, 206 |
209 | Arbaclofen ER Tablets | 1件: Arbaclofen Arbaclofen | 1件: D09791
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
210 | Arbaclofen Extended Release Tablets | 1件: Arbaclofen Arbaclofen | 1件: D09791
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
211 | Arbaclofen Placarbil | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: D08861
D08861
,
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
212 | Arbaclofen placarbil 15 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: D08861
D08861
,
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
213 | Arbaclofen placarbil 30 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: D08861
D08861
,
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
214 | Arbaclofen placarbil 45 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: D08861
D08861
,
D09791
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
215 | ARICEPT | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 4件: 6 6, 13, 78, 124 |
216 | Aricept 10 mg | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 |
217 | Aricept 10 mg filmdragerade tabletter | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 |
218 | Aricept 5 mg | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 |
219 | Aricept 5 mg filmdragerade tabletter | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 |
220 | Arm 1 - GEH120714 (18F) Injection | - | - | - | - | 1件: 13 13 |
221 | Armodafinil | 1件: Armodafinil Armodafinil | 1件: D03215
D03215
| 1件: SLC6A3 SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 3件: 6 6, 13, 84 |
222 | ARN-6039 | - | - | - | - | 1件: 13 13 |
223 | Arzerra | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
224 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
225 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
226 | Arzerra® | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
227 | ASA | - | - | - | - | 4件: 13 13, 96, 97, 251 |
228 | ASB-683699 | - | - | - | - | 1件: 13 13 |
229 | Aspirin | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 12件: 13 13, 22, 34, 46, 49, 51, 58, 86, 113, 158, 210, 231 |
230 | Aspirin 650mg Oral Capsule | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
231 | ATA188 | - | - | - | - | 1件: 13 13 |
232 | Atacicept | 1件: Atacicept Atacicept | 1件: D09704
D09704
| 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 13 13, 46, 49, 66 |
233 | Atacicept 150 mg | 1件: Atacicept Atacicept | 1件: D09704
D09704
| 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 13 13, 49 |
234 | Atacicept 25 mg | 1件: Atacicept Atacicept | 1件: D09704
D09704
| 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 13 13, 66 |
235 | Atacicept 75 mg | 1件: Atacicept Atacicept | 1件: D09704
D09704
| 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 13 13, 49, 66 |
236 | ATG | - | - | - | - | 4件: 13 13, 60, 96, 285 |
237 | ATL1102 | 1件: ATL1102 ATL1102 | - | - | - | 1件: 13 13 |
238 | Atomoxetine | 1件: Atomoxetine Atomoxetine | 2件: D02574
D02574
,
D07473
| 1件: SLC6A2 SLC6A2 💬 | 1件: Synaptic vesicle cycle Synaptic vesicle cycle 💬 | 4件: 6 6, 8, 13, 17 |
239 | Atorvastatin | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 18件: 13 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299 |
240 | ATX-MS-1467 | - | - | - | - | 1件: 13 13 |
241 | AUBAGIO | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
242 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
243 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
244 | Aubagio 14 mg film-coated tablets | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
245 | Aubagio® | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
246 | Autologous adipose derived mesenchymal cells | - | - | - | - | 1件: 13 13 |
247 | Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved | - | - | - | - | 1件: 13 13 |
248 | Autologous bone marrow transplantation | - | - | - | - | 2件: 13 13, 28 |
249 | Autologous Bone Marrow-Derived Mononuclear Stem Cells | - | - | - | - | 1件: 13 13 |
250 | Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope | - | - | - | - | 1件: 13 13 |
251 | Autologous Hematopoietic Stem Cell | - | - | - | - | 1件: 13 13 |
252 | Autologous hematopoietic stem cell transplant | - | - | - | - | 1件: 13 13 |
253 | Autologous Hematopoietic Stem Cell Transplantation | - | - | - | - | 7件: 11 11, 13, 14, 28, 49, 51, 84 |
254 | Autologous hematopoietic stem cells | - | - | - | - | 1件: 13 13 |
255 | Autologous Mesenchymal Cell Product | - | - | - | - | 1件: 13 13 |
256 | Autologous mesenchymal stem cell transplantation | - | - | - | - | 1件: 13 13 |
257 | Autologous mesenchymal stem cells | - | - | - | - | 5件: 2 2, 6, 13, 17, 46 |
258 | Autologous Stem Cell Transplantation | - | - | - | - | 4件: 13 13, 28, 56, 96 |
259 | Autologous Stem Cells | - | - | - | - | 2件: 13 13, 51 |
260 | AUTOLOGOUS T-LYMPHOCYTES | - | - | - | - | 1件: 13 13 |
261 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | - | - | - | - | 1件: 13 13 |
262 | AV605 | - | - | - | - | 1件: 13 13 |
263 | AVONEX | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 |
264 | Avonex (Interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
265 | Avonex (interferon beta-1a), Biogen Idec Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
266 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
267 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
268 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
269 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
270 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
271 | Avonex and Topamax | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
272 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
273 | Avonex prefilled syringe via manual IM injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
274 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
275 | Avonex/Betaseron/Copaxone/Rebif | 3件: Glatiramer Glatiramer, Interferon beta-1a, Interferon beta-1b | 3件: D00746
D00746
,
D04318
,
D04554
| 22件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, IFNAR1, IFNAR2 💬 | 44件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
276 | Avonex/Zocor | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
277 | AVONEX® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
278 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
279 | AVP-923 | - | - | - | - | 3件: 2 2, 6, 13 |
280 | Azathioprine | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
281 | Azathioprine (AZA) | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 3件: 13 13, 19, 97 |
282 | Azatioprina | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 3件: 13 13, 96, 97 |
283 | AZATIOPRINA HEX. 50CPR 50MG BL | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 1件: 13 13 |
284 | Azithromycin | 1件: Azithromycin Azithromycin | 3件: D02134
D02134
,
D06390
,
D07486
| - | - | 6件: 13 13, 84, 85, 96, 228, 299 |
285 | B001 injection | - | - | - | - | 1件: 13 13 |
286 | Bacille Calmette-Guerin vaccine | - | - | - | - | 1件: 13 13 |
287 | Bacille of Calmette-Guerin | - | - | - | - | 1件: 13 13 |
288 | Baclofen | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 7件: 2 2, 10, 13, 18, 65, 149, 206 |
289 | Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
290 | Baclofen ER Capsules (GRS) 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
291 | Baclofen ER Capsules (GRS) 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
292 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
293 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
294 | Baclofen ER Capsules (GRS) 50 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
295 | Baclofen IR | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
296 | Baclofen Tablets USP | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
297 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
298 | BAF312 | - | - | - | - | 2件: 13 13, 50 |
299 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 |
300 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 |
301 | BAF312 4 mg tablet | - | - | - | - | 1件: 13 13 |
302 | BAF312 hemifumarate | - | - | - | - | 2件: 13 13, 50 |
303 | BAF312A | - | - | - | - | 1件: 13 13 |
304 | Bafiertam | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: D11492
D11492
| - | - | 1件: 13 13 |
305 | Balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 8件: 6 6, 11, 13, 81, 113, 122, 149, 299 |
306 | Balance platform therapy | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
307 | Baminercept | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 13 13, 46, 53, 97 |
308 | Baseline disease modifying therapies (DMTs) | - | - | - | - | 1件: 13 13 |
309 | Baseline Treatment | - | - | - | - | 1件: 13 13 |
310 | BAT4406F | - | - | - | - | 1件: 13 13 |
311 | BAY 79-4998 | - | - | - | - | 1件: 13 13 |
312 | BAY86-5046 | - | - | - | - | 1件: 13 13 |
313 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 |
314 | Bazedoxifene | 1件: Bazedoxifene Bazedoxifene | - | - | - | 1件: 13 13 |
315 | Bazedoxifene Acetate | 2件: Acetate Acetate, Bazedoxifene | - | - | - | 1件: 13 13 |
316 | BBR 2778 | - | - | - | - | 2件: 11 11, 13 |
317 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
318 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 |
319 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 |
320 | BCD-063 | - | - | - | - | 1件: 13 13 |
321 | BCD-132 | - | - | - | - | 1件: 13 13 |
322 | BCD-132, 125 mg | - | - | - | - | 1件: 13 13 |
323 | BCD-132, 500 mg | - | - | - | - | 1件: 13 13 |
324 | BCG20-0134 | - | - | - | - | 1件: 13 13 |
325 | BEAM Regimen | - | - | - | - | 1件: 13 13 |
326 | Beetainterferoni -1a | - | - | - | - | 1件: 13 13 |
327 | Behavioral: 6 months weight resistance and balance program | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
328 | Behavioral: Adherence counseling | - | - | - | - | 1件: 13 13 |
329 | Behavioral: Assessment of disability | - | - | - | - | 1件: 13 13 |
330 | Behavioral: Assessment of impact of MS on cognition | - | - | - | - | 1件: 13 13 |
331 | Behavioral: B-HIPE (Brief High Impact Preparatory Experience) | - | - | - | - | 1件: 13 13 |
332 | Behavioral: Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
333 | Behavioral: Collaborative Care (CC) | - | - | - | - | 1件: 13 13 |
334 | Behavioral: Dietary Guidelines for Americans Diet | - | - | - | - | 1件: 13 13 |
335 | Behavioral: Impact of four week coaching program on dietary habits | - | - | - | - | 1件: 13 13 |
336 | Behavioral: learning | - | - | - | - | 1件: 13 13 |
337 | Behavioral: Medical Marijuana | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
338 | Behavioral: meditation | - | - | - | - | 1件: 13 13 |
339 | Behavioral: Modified Paleolithic Elimination diet | - | - | - | - | 1件: 13 13 |
340 | Behavioral: Motivational Interviewing | - | - | - | - | 1件: 13 13 |
341 | Behavioral: Physical Activity Together for PwMS and their CGs (PAT-MS) | - | - | - | - | 1件: 13 13 |
342 | Behavioral: self massage | - | - | - | - | 1件: 13 13 |
343 | Behavioral: Sleep quality and physical activity | - | - | - | - | 1件: 13 13 |
344 | Behavioral: Smoking | - | - | - | - | 1件: 13 13 |
345 | Behavioral: Step Tracking | - | - | - | - | 1件: 13 13 |
346 | Behavioral: Telephone-based Cognitive Behavioral Therapy | - | - | - | - | 1件: 13 13 |
347 | Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
348 | Behavioral: Water Tracking | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 13 13 |
349 | BELIMUMAB | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 12件: 11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 |
350 | Best Available Therapy (BAT) | - | - | - | - | 1件: 13 13 |
351 | Beta-1b interferoni | - | - | - | - | 1件: 13 13 |
352 | Beta-Alanine | 2件: Alanine Alanine, beta-Alanine | 2件: D00012
D00012
,
D07561
| - | - | 1件: 13 13 |
353 | Beta-alanine supplementation | 2件: Alanine Alanine, beta-Alanine | 2件: D00012
D00012
,
D07561
| - | - | 1件: 13 13 |
354 | Beta-Carotene | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
355 | Beta-Interferon | - | - | - | - | 1件: 13 13 |
356 | BETACAROTENE | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
357 | BETACONNECT | - | - | - | - | 1件: 13 13 |
358 | Betaconnect auto-injector | - | - | - | - | 1件: 13 13 |
359 | BETACONNECT auto-injector. | - | - | - | - | 1件: 13 13 |
360 | Betaconnect Autoinjector | - | - | - | - | 1件: 13 13 |
361 | BETACONNECT device | - | - | - | - | 1件: 13 13 |
362 | BETAFERON | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
363 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
364 | BETAFERON 250 mcg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
365 | Betaferon 250 microgram/ml | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
366 | Betaferon 250 microgram/ml, powder and solvent for solution for injection | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
367 | Betaferon 250 microgram/mL, powder and solvent for solution for injection. | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
368 | Betaferon 250 microgramos | - | - | - | - | 1件: 13 13 |
369 | Betaferon 250mcg | - | - | - | - | 1件: 13 13 |
370 | Betaferon 250µg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
371 | BETAFERON 500 mcg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
372 | Betaferon 500 µg | - | - | - | - | 1件: 13 13 |
373 | Betaferon 500mcg | - | - | - | - | 1件: 13 13 |
374 | Betaferon 500µg | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
375 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
376 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
377 | Betaferon, BAY86-5046 | - | - | - | - | 1件: 13 13 |
378 | Betaferon/Betaseron | - | - | - | - | 1件: 13 13 |
379 | Betaferon® | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
380 | BETAFERON® (interferon beta-1b) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
381 | Betaseron | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
382 | Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
383 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
384 | Better | - | - | - | - | 2件: 6 6, 13 |
385 | Bevacizumab | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 9件: 13 13, 34, 85, 86, 87, 89, 227, 280, 331 |
386 | Bexarotene | 1件: Bexarotene Bexarotene | 1件: D03106
D03106
| 3件: RXRA RXRA, RXRB, RXRG 💬 | 17件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 2件: 13 13, 75 |
387 | Bexsero | 1件: Neisseria meningitidis serogroup b nhba fusion protein antigen Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 6件: 11 11, 13, 61, 62, 66, 222 |
388 | BG-12 120 | - | - | - | - | 1件: 13 13 |
389 | BG00002 | - | - | - | - | 1件: 13 13 |
390 | BG00002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
391 | BG00002-E (natalizumab high titer) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
392 | BG00012 | - | - | - | - | 2件: 13 13, 46 |
393 | BG00012 (DMF) | - | - | - | - | 1件: 13 13 |
394 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 |
395 | BG0002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
396 | BG9418 (interferon beta 1-a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
397 | BG9418 (interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 |
398 | BGC20-0134 | - | - | - | - | 1件: 13 13 |
399 | BGG492 | - | - | - | - | 1件: 13 13 |
400 | BHT-3009 | - | - | - | - | 1件: 13 13 |
401 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 |
402 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 |
403 | BHT-3009-01 | - | - | - | - | 1件: 13 13 |
404 | BIIB 017 | - | - | - | - | 1件: 13 13 |
405 | BIIB017 | - | - | - | - | 1件: 13 13 |
406 | BIIB017 (Peginterferon beta-1a) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
407 | BIIB017 (peginterferon beta-1a) Autoinjector | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
408 | BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
409 | BIIB019 | - | - | - | - | 1件: 13 13 |
410 | BIIB019 (Daclizumab High Yield Process) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
411 | BIIB019 (Daclizumab) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
412 | BIIB033 | - | - | - | - | 1件: 13 13 |
413 | BIIB033 (ANTI-LINGO) | - | - | - | - | 1件: 13 13 |
414 | BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957 | - | - | - | - | 1件: 13 13 |
415 | BIIB033 (opicinumab) | 1件: Opicinumab Opicinumab | 1件: D11767
D11767
| 1件: LINGO1 LINGO1 💬 | - | 1件: 13 13 |
416 | BIIB041 | - | - | - | - | 1件: 13 13 |
417 | BIIB041 (fampridine) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
418 | BIIB041 (Fampridine-SR) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
419 | BIIB041 (PR Fampridine) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
420 | BIIB061 | - | - | - | - | 1件: 13 13 |
421 | BIIB133 | - | - | - | - | 1件: 13 13 |
422 | Biological samples | - | - | - | - | 1件: 13 13 |
423 | BIOTIN | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 5件: 2 2, 8, 10, 13, 20 |
424 | Biotina | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 2件: 8 8, 13 |
425 | BIRT 2584 XX | - | - | - | - | 1件: 13 13 |
426 | BIRT 2584XX | - | - | - | - | 1件: 13 13 |
427 | Bisacodyl | 1件: Bisacodyl Bisacodyl | 1件: D00245
D00245
| - | - | 1件: 13 13 |
428 | Blood sample | - | - | - | - | 18件: 8 8, 13, 46, 49, 51, 53, 61, 65, 66, 84, 96, 97, 107, 127, 235, 274, 288, 299 |
429 | Blood samples | - | - | - | - | 9件: 13 13, 41, 46, 51, 61, 97, 227, 240, 271 |
430 | Blood sampling | - | - | - | - | 6件: 13 13, 17, 19, 46, 51, 96 |
431 | BMMNC | - | - | - | - | 1件: 13 13 |
432 | BMS 188667 (Abatacept) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 13 13 |
433 | BNT162b2 | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
434 | BodyBio Balance Oil | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
435 | BodyBio PC | - | - | - | - | 1件: 13 13 |
436 | Bone marrow autologous mesenchymal stem cells transplantation | - | - | - | - | 1件: 13 13 |
437 | BORAGE OIL | 1件: Borage oil Borage oil | - | - | - | 1件: 13 13 |
438 | BORAGE OIL 20% GLA | 1件: Borage oil Borage oil | - | - | - | 1件: 13 13 |
439 | BORTEZOMIB | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 16件: 11 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331 |
440 | Bosentan | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 13 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 |
441 | BOSWELAN | - | - | - | - | 1件: 13 13 |
442 | Boswellia Serrata | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
443 | Boswellia Serrata Extract | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
444 | Boswellia serrata extract PS0201Bo capsules | 1件: Indian frankincense Indian frankincense | - | - | - | 1件: 13 13 |
445 | Boswellic acids (BOSWELAN) | - | - | - | - | 1件: 13 13 |
446 | Botox | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 6件: 2 2, 6, 13, 51, 149, 226 |
447 | Botox 100 UNT Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
448 | BOTOX® | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
449 | Botulinum Toxin | - | - | - | - | 3件: 6 6, 13, 149 |
450 | Botulinum toxin A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 4件: 13 13, 51, 149, 226 |
451 | BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
452 | BOTULINUM TOXIN TYPE A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 10件: 2 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 |
453 | Botulinum Toxin Type A 200U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
454 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
455 | Botulinum toxin type A infiltrations | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
456 | Brimonidine | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 90 |
457 | Brimonidine tartrate | 1件: Brimonidine Brimonidine | 2件: D02076
D02076
,
D07540
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 90 |
458 | BX-1 | - | - | - | - | 1件: 13 13 |
459 | C1-esterase inhibitor (Cinryze) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 13 13 |
460 | C105 | - | - | - | - | 1件: 13 13 |
461 | Caffeine | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 9件: 2 2, 6, 13, 21, 46, 78, 96, 97, 265 |
462 | Calcio | 1件: Calcium Calcium | - | - | - | 4件: 13 13, 96, 97, 274 |
463 | CALCIO FOLINATO DC.IT | 1件: Calcium Calcium | - | - | - | 1件: 13 13 |
464 | Calcium | 1件: Calcium Calcium | - | - | - | 30件: 3 3, 6, 13, 15, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 256, 265, 274, 298, 299 |
465 | Calcium and Vitamin D combination | 2件: Calcium Calcium, Vitamin D | - | - | - | 1件: 13 13 |
466 | Calcium carbonate | 3件: Calcium Calcium, Calcium carbonate, Carbonate ion | 2件: D00932
D00932
,
D10802
| - | - | 8件: 13 13, 19, 46, 53, 75, 96, 235, 299 |
467 | Calcium levofolinate | 1件: Calcium Calcium | - | - | - | 1件: 13 13 |
468 | Cannabidiol | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 18件: 6 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 |
469 | Cannabidiol (CBD) | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 7件: 6 6, 13, 140, 144, 145, 156, 158 |
470 | Cannabidiol / Dronabinol capsule 5 mg+2,5 mg | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: D00306
D00306
,
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
471 | Cannabidiol Botanical Drug Substance (CBD BDS) | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
472 | Cannabidiol capsule 5 mg | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
473 | Cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 9件: 2 2, 6, 13, 19, 46, 90, 96, 97, 271 |
474 | Cannabis Based Medicine Extract (Sativex) | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
475 | Cannabis, Medical | 1件: Medical Cannabis Medical Cannabis | - | - | - | 5件: 2 2, 6, 13, 96, 97 |
476 | Cannador | - | - | - | - | 1件: 13 13 |
477 | Capacity of muscular oxygen extraction | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 13 13 |
478 | Caprylic Triglyceride | 1件: Tricaprylin Tricaprylin | - | - | - | 1件: 13 13 |
479 | Capsules with 160 mg Teavigo (at least 94% EGCG) | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 13 13 |
480 | Carbamazepine | 1件: Carbamazepine Carbamazepine | 1件: D00252
D00252
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 2件: 13 13, 231 |
481 | Carbidopa | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 9件: 2 2, 4, 6, 13, 17, 90, 140, 164, 201 |
482 | Carbonate | 1件: Carbonate ion Carbonate ion | - | - | - | 12件: 2 2, 13, 17, 18, 19, 46, 53, 75, 96, 127, 235, 299 |
483 | Carmustine | 1件: Carmustine Carmustine | 1件: D00254
D00254
| - | - | 5件: 11 11, 13, 14, 28, 60 |
484 | Carmustine, etoposide, cytarabine, and melphalan (BEAM) | 4件: Carmustine Carmustine, Cytarabine, Etoposide, Melphalan | 7件: D00125
D00125
,
D00168
,
D00254
,
D00369
,
D03046
,
D03637
,
D04107
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
485 | Carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 9件: 5 5, 13, 58, 86, 96, 97, 265, 298, 316 |
486 | Carnosine | 1件: Carnosine Carnosine | - | - | - | 2件: 6 6, 13 |
487 | Carnosine, capsulle, 2 g/day, 8 weeks | 1件: Carnosine Carnosine | - | - | - | 1件: 13 13 |
488 | CBD | - | - | - | - | 12件: 2 2, 6, 8, 13, 36, 46, 140, 144, 145, 156, 158, 206 |
489 | CC | - | - | - | - | 14件: 13 13, 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 |
490 | CCI-779 | - | - | - | - | 2件: 13 13, 46 |
491 | CD | - | - | - | - | 7件: 6 6, 13, 46, 51, 96, 97, 265 |
492 | CDP323 | 1件: CDP323 CDP323 | - | - | - | 1件: 13 13 |
493 | CELLCEPT | - | - | - | - | 5件: 11 11, 13, 42, 43, 49 |
494 | Cellular therapy with EBV specific autologous CTL infusion | - | - | - | - | 1件: 13 13 |
495 | Ceralifimod | 1件: Ceralifimod Ceralifimod | - | - | - | 1件: 13 13 |
496 | Ceralifmod | - | - | - | - | 1件: 13 13 |
497 | Cerebro-spinal fluid | - | - | - | - | 1件: 13 13 |
498 | Cesamet™ (nabilone) | 1件: Nabilone Nabilone | 1件: D05099
D05099
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
499 | Ceterizine | - | - | - | - | 1件: 13 13 |
500 | Cetirizina | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 3件: 13 13, 28, 300 |
501 | Cetirizina Mylan Generics | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
502 | Cetirizine | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 35 |
503 | CETIRIZINE HYDROCHLORIDE | 1件: Cetirizine Cetirizine | 2件: D00664
D00664
,
D07662
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
504 | CGP 77116 | - | - | - | - | 1件: 13 13 |
505 | Charcoal | - | - | - | - | 1件: 13 13 |
506 | Chloride | 1件: Chloride ion Chloride ion | - | - | - | 29件: 6 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 271, 288, 296, 297, 299, 338 |
507 | CHOLECALCIFEROL | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 10件: 13 13, 19, 34, 46, 49, 75, 96, 97, 298, 299 |
508 | Cholecalciferol (Vitamin D3) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 13 13, 299 |
509 | Cholecalciferol, Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
510 | Cholestyramine | 1件: Cholestyramine Cholestyramine | - | - | - | 2件: 13 13, 79 |
511 | CHR-1103 / GBR500 | - | - | - | - | 1件: 13 13 |
512 | Cianocobalamina | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 13 13 |
513 | CIANOCOBALAMINA FU DC.IT | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 13 13 |
514 | CIC using LoFric Primo | - | - | - | - | 1件: 13 13 |
515 | Ciclofosfamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
516 | Cinryze | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 2件: 13 13, 61 |
517 | Circadin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 3件: 6 6, 13, 90 |
518 | Circadin ( INN= Melatonin) | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
519 | CISAPRIDE | 1件: Cisapride Cisapride | 2件: D00274
D00274
,
D02092
| 3件: HTR2A HTR2A, HTR3A, HTR4 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
520 | Citalopram | 1件: Citalopram Citalopram | 2件: D00822
D00822
,
D07704
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 7件: 6 6, 8, 13, 18, 46, 98, 127 |
521 | CITOCHINE ED IMMUNOMODULATORI | - | - | - | - | 1件: 13 13 |
522 | CLADRIBINA | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
523 | Cladribina oral | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
524 | CLADRIBINE | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 11 11, 13, 94 |
525 | Cladribine (MAVENCLAD®) | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
526 | Cladribine 3.5 mg/kg | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
527 | Cladribine 5.25 mg/kg | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
528 | Cladribine Oral Tablet | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
529 | Cladribine Tablet | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
530 | Cladribine Tablets | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
531 | Clemastine | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
532 | CLEMASTINE FUMARATE | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
533 | Clemastine Milstein 1 mg, tabletten | 1件: Clemastine Clemastine | 2件: D00666
D00666
,
D03535
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
534 | Clostridium botulinum | 1件: Clostridium botulinum Clostridium botulinum | - | - | - | 1件: 13 13 |
535 | CLOSTRIDIUM BOTULINUM TOXIN TYPE A | 2件: Botulinum toxin type A Botulinum toxin type A, Clostridium botulinum | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
536 | CNM-Au8 | - | - | - | - | 2件: 2 2, 13 |
537 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 |
538 | CNTO 1275 | - | - | - | - | 2件: 13 13, 96 |
539 | CO | - | - | - | - | 6件: 6 6, 13, 53, 70, 85, 149 |
540 | CO-14 | - | - | - | - | 1件: 13 13 |
541 | Coconut | 1件: Coconut Coconut | - | - | - | 3件: 13 13, 53, 226 |
542 | Coconut oil | 2件: Coconut Coconut, Coconut oil | 1件: D05326
D05326
| - | - | 2件: 13 13, 226 |
543 | Coconut oil and epigallocatechin gallate | 4件: Coconut Coconut, Coconut oil, Epigallocatechin, Epigallocatechin gallate | 1件: D05326
D05326
| - | - | 1件: 13 13 |
544 | Coenzyme Q | - | - | - | - | 1件: 13 13 |
545 | COLECALCIFEROL | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 4件: 13 13, 46, 96, 228 |
546 | COLECALCIFEROL CONCENTRATE (OILY FORM) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
547 | Combination Product: ofatumumab with AI | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
548 | Combination Product: ofatumumab with PRF | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
549 | Comirnaty | 1件: Pfizer-BioNTech COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine | 1件: D11971
D11971
| - | - | 5件: 13 13, 46, 51, 53, 299 |
550 | Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion | 1件: Pfizer-BioNTech COVID-19 Vaccine Pfizer-BioNTech COVID-19 Vaccine | 1件: D11971
D11971
| - | - | 1件: 13 13 |
551 | Continued Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
552 | COP | - | - | - | - | 1件: 13 13 |
553 | COP-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
554 | COP-1/Copolymer-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
555 | COPAXONE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
556 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE 28 SIRINGHE PRERIEMPITE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
557 | COPAXONE - 20 MG/ML SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE 30 SIRINGHE | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
558 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
559 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
560 | Copaxone 20 mg | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
561 | Copaxone 20 mg/ml | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
562 | COPAXONE 20 mg/ml solución inyectable en jeringa precargada | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
563 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
564 | Copaxone 20 mg/ml Solution for Injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
565 | Copaxone 20 mg/ml, Solution for Injection, pre-filled syringes | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
566 | Copaxone 20mg/ml Solution for Injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
567 | Copaxone 40 mg/ml | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
568 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
569 | Copaxone subcutaneous injection syringe | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
570 | COPAXONE*SC 28SIR 20MG/ML | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
571 | Copaxone-Teva | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
572 | Copaxone® | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
573 | Copolymer 1 | - | - | - | - | 1件: 13 13 |
574 | Copolymer-1 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
575 | Corticosteroid | - | - | - | - | 10件: 13 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
576 | Corticosteroids & tanCART19/20 | - | - | - | - | 1件: 13 13 |
577 | Corticotropin | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 9件: 2 2, 13, 46, 75, 78, 81, 84, 205, 222 |
578 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 |
579 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 |
580 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 |
581 | COVID-19 vaccination | - | - | - | - | 1件: 13 13 |
582 | COVID19 vaccine | - | - | - | - | 1件: 13 13 |
583 | Cranberry | 1件: Cranberry Cranberry | - | - | - | 1件: 13 13 |
584 | Creatine | 1件: Creatine Creatine | - | - | - | 16件: 1 1, 2, 3, 5, 6, 8, 13, 15, 21, 46, 49, 50, 113, 156, 201, 256 |
585 | CRM197 | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 3件: 11 11, 13, 46 |
586 | CS-0777 tablets | - | - | - | - | 1件: 13 13 |
587 | CSF sampling | - | - | - | - | 1件: 13 13 |
588 | CT103A cells | - | - | - | - | 1件: 13 13 |
589 | Curcumin | 1件: Curcumin Curcumin | - | - | - | 11件: 2 2, 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
590 | Cyclophosfamide | - | - | - | - | 1件: 13 13 |
591 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
592 | Cyclophosphamide (drug) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
593 | Cyclophosphamide and ATG | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
594 | Cyclophosphamide and fludarabine | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
595 | CYCLOPHOSPHAMIDE MONOHYDRATE | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 4件: 13 13, 60, 96, 256 |
596 | Cyclophosphamide/Glatiramer acetate | 3件: Acetate Acetate, Cyclophosphamide, Glatiramer | 3件: D00287
D00287
,
D04318
,
D07760
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
597 | CYMBALTA | - | - | - | - | 3件: 6 6, 13, 49 |
598 | Cysteine | 1件: Cysteine Cysteine | 2件: D00026
D00026
,
D02326
| - | - | 11件: 6 6, 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 |
599 | Cytarabine | 1件: Cytarabine Cytarabine | 3件: D00168
D00168
,
D03046
,
D03637
| - | - | 7件: 11 11, 13, 14, 25, 49, 60, 65 |
600 | Cytolytic CD4+ T cells | - | - | - | - | 1件: 13 13 |
601 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
602 | Células madre mesenquimales | - | - | - | - | 1件: 13 13 |
603 | D Mannose | 1件: Mannose Mannose | - | - | - | 1件: 13 13 |
604 | D-aspartate | - | - | - | - | 1件: 13 13 |
605 | D-BIOTIN | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 3件: 10 10, 13, 20 |
606 | D-BIOTINA | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 1件: 13 13 |
607 | DAC | - | - | - | - | 1件: 13 13 |
608 | DAC HYP | - | - | - | - | 1件: 13 13 |
609 | DAC-HYP | - | - | - | - | 1件: 13 13 |
610 | DACLIZUMAB | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
611 | Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
612 | Daclizumab High Yield Process | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
613 | DACLIZUMAB HYP | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
614 | Daclizumab HYP (DAC HYP | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
615 | Daclizumab HYP (DAC HYP) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
616 | Daclizumab wih Greek suffix | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
617 | Daclizumab with Greek suufix | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
618 | Dalfampridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 4 4, 13 |
619 | Dalfampridine ER | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
620 | Dalfampridine-ER 10mg | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
621 | Dalfampridine-ER 5mg | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
622 | Dantrolene | 1件: Dantrolene Dantrolene | 2件: D02274
D02274
,
D02347
| - | - | 2件: 13 13, 233 |
623 | DAPIROLIZUMAB PEGOL | 1件: Dapirolizumab pegol Dapirolizumab pegol | - | - | - | 2件: 13 13, 49 |
624 | Darifenacin | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 2件: 6 6, 13 |
625 | Darifenacin (BAY79-4998) | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
626 | DC-TAB | - | - | - | - | 1件: 13 13 |
627 | Dekristol | - | - | - | - | 2件: 13 13, 97 |
628 | Dekristol 20000 IE | - | - | - | - | 1件: 13 13 |
629 | Dekristol® 400-Tabletten | - | - | - | - | 1件: 13 13 |
630 | Dekristol®-Tablette 1 (400 IE) | - | - | - | - | 1件: 13 13 |
631 | Delta-9-tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 3件: 8 8, 13, 36 |
632 | DEMESTRIL SEPTEM | - | - | - | - | 1件: 13 13 |
633 | Desloratadine | 1件: Desloratadine Desloratadine | 1件: D03693
D03693
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
634 | Desloratadine given orally | 1件: Desloratadine Desloratadine | 1件: D03693
D03693
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
635 | Dexamethason | - | - | - | - | 4件: 13 13, 28, 46, 331 |
636 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 25件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
637 | Dexamethasone given orally | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
638 | Dexamethasone soduim phosphate | 2件: Dexamethasone Dexamethasone, Phosphate ion | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
639 | Dexchlorpheniramine | 1件: Dexchlorpheniramine Dexchlorpheniramine | 1件: D07803
D07803
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 49 |
640 | Dexrazoxane | 1件: Dexrazoxane Dexrazoxane | 1件: D03730
D03730
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
641 | Dexrazoxane (DRZ) plus Mitoxantrone (MX) | 2件: Dexrazoxane Dexrazoxane, Mitoxantrone | 3件: D02166
D02166
,
D03730
,
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
642 | Dextromethorphan | 1件: Dextromethorphan Dextromethorphan | 3件: D00848
D00848
,
D03742
,
D03744
| 6件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
643 | DEXTROMETHORPHAN HYDROBROMIDE | 1件: Dextromethorphan Dextromethorphan | 3件: D00848
D00848
,
D03742
,
D03744
| 6件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 2件: 13 13, 46 |
644 | Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 7件: D00642
D00642
,
D00643
,
D00848
,
D02272
,
D03742
,
D03744
,
D08458
| 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 |
645 | Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 7件: D00642
D00642
,
D00643
,
D00848
,
D02272
,
D03742
,
D03744
,
D08458
| 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 |
646 | Dextromethorphan/Quinidine | 2件: Dextromethorphan Dextromethorphan, Quinidine | 7件: D00642
D00642
,
D00643
,
D00848
,
D02272
,
D03742
,
D03744
,
D08458
| 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
647 | Dextrometorfano | 1件: Dextromethorphan Dextromethorphan | 3件: D00848
D00848
,
D03742
,
D03744
| 6件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 13 13 |
648 | DEXTROMETORFANO HIDROBROMURO | 1件: Dextromethorphan Dextromethorphan | 3件: D00848
D00848
,
D03742
,
D03744
| 6件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SIGMAR1 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 13 13 |
649 | Dextrometorfano/Quinidina | 2件: Dextromethorphan Dextromethorphan, Quinidine | 7件: D00642
D00642
,
D00643
,
D00848
,
D02272
,
D03742
,
D03744
,
D08458
| 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
650 | Diagnostic Test: Entire-body PET-CT scans | - | - | - | - | 1件: 13 13 |
651 | Diagnostic Test: Nicotine and cotinine serum levels | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 13 13 |
652 | Diagnostic Test: Oral glucose tolerance test | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 3件: 13 13, 65, 299 |
653 | Diagnostic Test: PET with [11C]Flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 |
654 | Diagnostic Test: Stroop test | - | - | - | - | 1件: 13 13 |
655 | Diagnostic Test: Testing of autonomous nervous system function | - | - | - | - | 1件: 13 13 |
656 | Diazoxide | 1件: Diazoxide Diazoxide | 1件: D00294
D00294
| 2件: ABCC8 ABCC8, KCNJ11 💬 | 4件: ABC transporters ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus 💬 | 2件: 13 13, 193 |
657 | DIBASE | - | - | - | - | 1件: 13 13 |
658 | Diclofenac | 1件: Diclofenac Diclofenac | 3件: D00903
D00903
,
D00904
,
D07816
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 5件: 13 13, 34, 46, 78, 271 |
659 | Diclofenac sodium topical gel | 1件: Diclofenac Diclofenac | 3件: D00903
D00903
,
D00904
,
D07816
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
660 | Dietary Supplement: vitamin A | 1件: Vitamin A Vitamin A | 2件: D00069
D00069
,
D06543
| 2件: RARA RARA, RARB 💬 | 8件: Acute myeloid leukemia Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 13 13 |
661 | DIMETHYL FUMARATE | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 4件: 13 13, 51, 86, 296 |
662 | Dimethyl Fumarate (DMF) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 3件: 13 13, 51, 86 |
663 | Dimethyl fumarate 240 mg | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
664 | Dimethyl fumarate [DMF] | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
665 | DIMETIL-FUMARATO | - | - | - | - | 1件: 13 13 |
666 | Dimetilfumarato | - | - | - | - | 1件: 13 13 |
667 | Diphenhydramine | 1件: Diphenhydramine Diphenhydramine | 6件: D00300
D00300
,
D00669
,
D02419
,
D03285
,
D03360
,
D03854
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 10件: 11 11, 13, 49, 51, 70, 86, 96, 222, 256, 300 |
668 | Diphenhydramine IV | 1件: Diphenhydramine Diphenhydramine | 6件: D00300
D00300
,
D00669
,
D02419
,
D03285
,
D03360
,
D03854
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
669 | Diphenydramine | - | - | - | - | 1件: 13 13 |
670 | Diphtheria toxoid | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 46 |
671 | Diroximel fumarate | 1件: Diroximel fumarate Diroximel fumarate | 1件: D11154
D11154
| - | - | 1件: 13 13 |
672 | Diroximel Fumarate (DRF) | 1件: Diroximel fumarate Diroximel fumarate | 1件: D11154
D11154
| - | - | 1件: 13 13 |
673 | Dirucotide | 1件: Dirucotide Dirucotide | 1件: D09396
D09396
| - | - | 1件: 13 13 |
674 | Dirucotide acetate | 2件: Acetate Acetate, Dirucotide | 1件: D09396
D09396
| - | - | 1件: 13 13 |
675 | Discontinuation of disease modifying therapy | - | - | - | - | 1件: 13 13 |
676 | Disease Modifying therapy | - | - | - | - | 1件: 13 13 |
677 | Disease modifying treatment (DMT) | - | - | - | - | 1件: 13 13 |
678 | DMT | - | - | - | - | 1件: 13 13 |
679 | DMT continuation | - | - | - | - | 1件: 13 13 |
680 | Domperidone | 1件: Domperidone Domperidone | 2件: D01745
D01745
,
D07868
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 5件: 6 6, 13, 17, 51, 230 |
681 | Donepezil | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 9件: 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
682 | Donepezil HCI (drug) | 1件: Donepezil Donepezil | 2件: D00670
D00670
,
D07869
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 |
683 | Dosing Interruption of Natalizumab | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
684 | Dotarem | 1件: Gadoteric acid Gadoteric acid | 1件: D08007
D08007
| - | - | 1件: 13 13 |
685 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: D08007
D08007
| - | - | 1件: 13 13 |
686 | Doxycycline | 1件: Doxycycline Doxycycline | 5件: D00307
D00307
,
D02129
,
D03903
,
D03904
,
D07876
| - | - | 16件: 13 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 161, 162, 167, 227, 280, 299 |
687 | DPA | - | - | - | - | 5件: 2 2, 6, 13, 85, 127 |
688 | DPA-714 PET/MRI | - | - | - | - | 1件: 13 13 |
689 | Dronabinol | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 5件: 2 2, 13, 46, 271, 298 |
690 | Dronabinol 25 mg/ml, oral drops | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
691 | Dronabinol capsule 2,5 mg | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
692 | Drug - SHR1459 | - | - | - | - | 1件: 13 13 |
693 | Duloxetine | 1件: Duloxetine Duloxetine | 2件: D01179
D01179
,
D07880
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 2件: 6 6, 13 |
694 | Duloxetine Hydrochloride (HCI) | 1件: Duloxetine Duloxetine | 2件: D01179
D01179
,
D07880
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
695 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 |
696 | DYDROGESTERONE | 1件: Dydrogesterone Dydrogesterone | 1件: D01217
D01217
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
697 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging | - | - | - | - | 1件: 13 13 |
698 | Dynamic Vessel Analyzer (DVA) | - | - | - | - | 1件: 13 13 |
699 | Dysport | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 2件: 13 13, 36 |
700 | DYSPORT*SC IM 2FL 500U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
701 | DYSPORT® | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
702 | Early Harvest Extra Virgin Olive Oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
703 | Early Highly Effective Therapies Group | - | - | - | - | 1件: 13 13 |
704 | EBIXA | 1件: Memantine Memantine | 2件: D04905
D04905
,
D08174
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 3件: 2 2, 6, 13 |
705 | ECP002A | - | - | - | - | 1件: 13 13 |
706 | ECULIZUMAB | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 11 11, 13, 14, 61, 62, 109, 222 |
707 | EFALIZUMAB | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 8件: 11 11, 13, 37, 46, 53, 61, 95, 96 |
708 | EGb 761® (Tanakan®) | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 13 13 |
709 | EGCG | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 9件: 6 6, 8, 13, 17, 28, 85, 113, 206, 299 |
710 | EHP-101 25 mg BID | - | - | - | - | 1件: 13 13 |
711 | EHP-101 25 mg OD | - | - | - | - | 1件: 13 13 |
712 | EHP-101 50 mg BID | - | - | - | - | 1件: 13 13 |
713 | EHP-101 50 mg OD | - | - | - | - | 1件: 13 13 |
714 | EK-12 | - | - | - | - | 1件: 13 13 |
715 | Elezanumab | 1件: Elezanumab Elezanumab | 1件: D11355
D11355
| 1件: RGMA RGMA 💬 | 2件: Axon guidance Axon guidance, TGF-beta signaling pathway 💬 | 1件: 13 13 |
716 | ELND002 | - | - | - | - | 1件: 13 13 |
717 | EMD 28162 | - | - | - | - | 1件: 13 13 |
718 | Emselex | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
719 | EMSELEX 15 mg Retardtabletten | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
720 | EMSELEX 7,5 mg Retardtabletten | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
721 | ENA713 | - | - | - | - | 2件: 6 6, 13 |
722 | Encapsulated Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
723 | Encapsulated Simvastatin tablets | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
724 | ENDOXAN | - | - | - | - | 7件: 13 13, 28, 43, 44, 85, 96, 222 |
725 | Endoxan - ciclofosfamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 13 13 |
726 | ENDOXAN BAXTER | - | - | - | - | 3件: 13 13, 43, 96 |
727 | Enriched Hematopoetic Stem Cell Infusion | - | - | - | - | 3件: 13 13, 19, 284 |
728 | Enspryng | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
729 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 |
730 | Epigallocatechin | 1件: Epigallocatechin Epigallocatechin | - | - | - | 5件: 8 8, 13, 28, 85, 113 |
731 | Epigallocatechin gallate | 2件: Epigallocatechin Epigallocatechin, Epigallocatechin gallate | - | - | - | 1件: 13 13 |
732 | Epigallocatechin-gallate (Sunphenon) | 1件: Epigallocatechin Epigallocatechin | - | - | - | 1件: 13 13 |
733 | EPO | - | - | - | - | 1件: 13 13 |
734 | Epoetin alfa | 1件: Erythropoietin Erythropoietin | 1件: D03231
D03231
| 1件: EPOR EPOR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 3件: 13 13, 18, 46 |
735 | Epoetin beta | 1件: Erythropoietin Erythropoietin | 1件: D03231
D03231
| 1件: EPOR EPOR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 13 13 |
736 | Equal | - | - | - | - | 5件: 6 6, 13, 67, 86, 230 |
737 | Erypo/Erypo FS | - | - | - | - | 1件: 13 13 |
738 | ERYTHROPOIETIN | 1件: Erythropoietin Erythropoietin | 1件: D03231
D03231
| 1件: EPOR EPOR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 9件: 2 2, 6, 13, 18, 22, 47, 70, 95, 96 |
739 | Escalation Therapies Group | - | - | - | - | 1件: 13 13 |
740 | Escitalopram | 1件: Escitalopram Escitalopram | 3件: D02567
D02567
,
D07704
,
D07913
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 3件: 2 2, 6, 13 |
741 | Escitalopram oxalate antidepressant | 1件: Escitalopram Escitalopram | 3件: D02567
D02567
,
D07704
,
D07913
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
742 | Esomeprazole | 1件: Esomeprazole Esomeprazole | 4件: D01984
D01984
,
D04056
,
D07917
,
D09339
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 8件: 13 13, 46, 86, 98, 107, 113, 298, 299 |
743 | Essential - hydroxytyrosol | 1件: Hydroxytyrosol Hydroxytyrosol | - | - | - | 1件: 13 13 |
744 | Essential fatty acids | - | - | - | - | 1件: 13 13 |
745 | Estradiol | 1件: Estradiol Estradiol | 8件: D00105
D00105
,
D01413
,
D01617
,
D01953
,
D04061
,
D04063
,
D04064
,
D04065
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 7件: 13 13, 46, 49, 65, 76, 226, 299 |
746 | ESTRADIOL HEMIHYDRATE | 1件: Estradiol Estradiol | 8件: D00105
D00105
,
D01413
,
D01617
,
D01953
,
D04061
,
D04063
,
D04064
,
D04065
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 13 13 |
747 | Estriol | 1件: Estriol Estriol | 2件: D00185
D00185
,
D01986
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 13 13, 227 |
748 | Estroprogestins | - | - | - | - | 1件: 13 13 |
749 | Eszopiclone | 1件: Eszopiclone Eszopiclone | 1件: D02624
D02624
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 3件: 6 6, 13, 46 |
750 | ETHINYLESTRADIOL | 1件: Ethinylestradiol Ethinylestradiol | 1件: D00554
D00554
| 1件: ESR1 ESR1 💬 | 9件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 13 13 |
751 | Etifoxine | 1件: Etifoxine Etifoxine | 1件: D07320
D07320
| - | - | 1件: 13 13 |
752 | ETIMS | - | - | - | - | 1件: 13 13 |
753 | ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) | - | - | - | - | 1件: 13 13 |
754 | Etoposide | 1件: Etoposide Etoposide | 2件: D00125
D00125
,
D04107
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 11件: 11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
755 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 |
756 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 |
757 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 |
758 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 |
759 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 |
760 | EVOBRUTINIB | 1件: Evobrutinib Evobrutinib | - | - | - | 3件: 13 13, 46, 49 |
761 | Evobrutinib 10mg | 1件: Evobrutinib Evobrutinib | - | - | - | 1件: 13 13 |
762 | Evobrutinib 25mg | 1件: Evobrutinib Evobrutinib | - | - | - | 1件: 13 13 |
763 | EXELON | 1件: Rivastigmine Rivastigmine | 2件: D02558
D02558
,
D03822
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 2件: 6 6, 13 |
764 | Exelon transdermales Pflaster | - | - | - | - | 1件: 13 13 |
765 | Exergame | - | - | - | - | 2件: 6 6, 13 |
766 | Experimental Glatiramer Acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
767 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 |
768 | EXTAVIA | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
769 | Extavia (interferon beta-1b), Novartis Pharma AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
770 | Extavia 250 microgram/ml | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
771 | Extavia 250 micrograms/ml | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
772 | EXTAVIA*SC 15FL 250MCG/ML+15SI | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
773 | Extavia® | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
774 | Extended release fampridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
775 | Extended-release oxycodone | 1件: Oxycodone Oxycodone | 3件: D03783
D03783
,
D05312
,
D05462
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
776 | Extended-release quetiapine fumarate | 1件: Quetiapine Quetiapine | 2件: D00458
D00458
,
D08456
| 2件: DRD2 DRD2, HTR2A 💬 | 11件: Alcoholism Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway 💬 | 1件: 13 13 |
777 | Extracorporeal Photopheresis | - | - | - | - | 3件: 13 13, 46, 96 |
778 | F-18 3F4AP | - | - | - | - | 1件: 13 13 |
779 | F-18 FEDAA1106 (BAY85-8101) | - | - | - | - | 1件: 13 13 |
780 | Famciclovir | 1件: Famciclovir Famciclovir | 1件: D00317
D00317
| - | - | 1件: 13 13 |
781 | FAMPRIDINA | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
782 | FAMPRIDINE | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 13 13, 14 |
783 | Fampridine SR | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
784 | Fampridine-SR | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
785 | Fampridine-SR b.i.d. (Twice Daily) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
786 | FAMPYRA | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 13 13, 14 |
787 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
788 | Fampyra 10 mg prolonged-release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
789 | Fampyra 10mg prolonged release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
790 | Fatigue | - | - | - | - | 1件: 13 13 |
791 | Febuxostat | 1件: Febuxostat Febuxostat | 1件: D01206
D01206
| 1件: XDH XDH 💬 | 5件: Caffeine metabolism Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism 💬 | 3件: 2 2, 6, 13 |
792 | Fecal microbial transplant (FMT) | - | - | - | - | 1件: 13 13 |
793 | Fecal Microbial Transplants | - | - | - | - | 1件: 13 13 |
794 | Fecal microbiota | - | - | - | - | 3件: 13 13, 96, 97 |
795 | Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool | - | - | - | - | 1件: 13 13 |
796 | Femoston 1/10 | - | - | - | - | 1件: 13 13 |
797 | Femoston 2/10 | - | - | - | - | 1件: 13 13 |
798 | FENEBRUTINIB | 1件: Fenebrutinib Fenebrutinib | 1件: D11457
D11457
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 13 13 |
799 | Feraheme | 1件: Ferumoxytol Ferumoxytol | 1件: D04177
D04177
| - | - | 1件: 13 13 |
800 | Ferumoxytol | 1件: Ferumoxytol Ferumoxytol | 1件: D04177
D04177
| - | - | 1件: 13 13 |
801 | Fexofenadine | 1件: Fexofenadine Fexofenadine | 2件: D00671
D00671
,
D07958
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 46 |
802 | Filgrastim | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 28件: 2 2, 6, 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
803 | Fingolimob | - | - | - | - | 1件: 13 13 |
804 | Fingolimob (FTY) | - | - | - | - | 1件: 13 13 |
805 | FINGOLIMOD | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 14, 156 |
806 | Fingolimod (FTY720) | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 156 |
807 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
808 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
809 | Fingolimod 1.25 mg | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
810 | FINGOLIMOD HYDROCHLORIDE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 |
811 | Fingolimodi | - | - | - | - | 1件: 13 13 |
812 | Fingolmod | - | - | - | - | 1件: 13 13 |
813 | Firategrast | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
814 | Firategrast (USAN approved name) | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
815 | Firategrast 150 mg | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
816 | Firategrast 300 mg | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
817 | Firategrast gastro-retentive solution | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
818 | Firategrast immediate release tablet | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
819 | Firategrast modified release tablet | 1件: Firategrast Firategrast | 1件: D06590
D06590
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
820 | First line DMT | - | - | - | - | 1件: 13 13 |
821 | Fish Oil | 1件: Fish oil Fish oil | - | - | - | 7件: 13 13, 46, 49, 66, 96, 260, 299 |
822 | Fish oil concentrate | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 |
823 | FISH OIL, RICH IN OMEGA-3-ACIDS | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 13 13 |
824 | FISH OIL,RICH IN OMEGA 3 ACIDS | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 |
825 | FLUDARA | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
826 | Fludarabine | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 18件: 13 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
827 | Flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 5件: 6 6, 13, 17, 18, 206 |
828 | Fluoxetin | 1件: Fluoxetine Fluoxetine | 2件: D00326
D00326
,
D00823
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 3件: 13 13, 179, 206 |
829 | Fluoxetin Hexal | 1件: Fluoxetine Fluoxetine | 2件: D00326
D00326
,
D00823
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
830 | FLUOXETINE | 1件: Fluoxetine Fluoxetine | 2件: D00326
D00326
,
D00823
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 4件: 13 13, 17, 78, 86 |
831 | FLUOXETINE HYDROCHLORIDE | 1件: Fluoxetine Fluoxetine | 2件: D00326
D00326
,
D00823
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 13 13 |
832 | Flupirtin | - | - | - | - | 1件: 13 13 |
833 | Flupirtine | 1件: Flupirtine Flupirtine | 1件: D07978
D07978
| - | - | 1件: 13 13 |
834 | Flupirtinmaleat | - | - | - | - | 1件: 13 13 |
835 | FLURBIPROFEN | 1件: Flurbiprofen Flurbiprofen | 3件: D00330
D00330
,
D01475
,
D02290
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 3件: 13 13, 21, 46 |
836 | FMP30 Donor Stool | - | - | - | - | 1件: 13 13 |
837 | Folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 4件: 13 13, 41, 46, 49 |
838 | FolateScan (Technetium Tc 99mEC20) | - | - | - | - | 4件: 13 13, 46, 49, 96 |
839 | Foralumab | 1件: Foralumab Foralumab | - | - | - | 2件: 13 13, 96 |
840 | Formistin | - | - | - | - | 1件: 13 13 |
841 | FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE | - | - | - | - | 1件: 13 13 |
842 | Formistin 10 mg | - | - | - | - | 1件: 13 13 |
843 | Formulation A | - | - | - | - | 1件: 13 13 |
844 | Formulation B | - | - | - | - | 1件: 13 13 |
845 | Formulation C | - | - | - | - | 1件: 13 13 |
846 | Formulation D | - | - | - | - | 1件: 13 13 |
847 | Four-point cane (FPC) | - | - | - | - | 1件: 13 13 |
848 | Fourier Domain Doppler Optical Coherence Tomography (FDOCT) | - | - | - | - | 1件: 13 13 |
849 | FPC | - | - | - | - | 1件: 13 13 |
850 | FTY720 | - | - | - | - | 2件: 13 13, 14 |
851 | FTY720D | - | - | - | - | 1件: 13 13 |
852 | Full Spectrum vitamin | - | - | - | - | 1件: 13 13 |
853 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 |
854 | Fumaric acid | 1件: Fumaric acid Fumaric acid | 1件: D02308
D02308
| - | - | 1件: 13 13 |
855 | Fusion | 1件: Iron polymaltose Iron polymaltose | - | - | - | 7件: 11 11, 13, 46, 49, 69, 70, 271 |
856 | G-CSF | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 16件: 2 2, 6, 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 |
857 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 |
858 | GA | - | - | - | - | 1件: 13 13 |
859 | GA 20 mg/mL | - | - | - | - | 1件: 13 13 |
860 | GA 40 mg/mL | - | - | - | - | 1件: 13 13 |
861 | GA Depot | - | - | - | - | 1件: 13 13 |
862 | GA Depot 25mg once monthly | - | - | - | - | 1件: 13 13 |
863 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 |
864 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 |
865 | GA Depot 80 mg | - | - | - | - | 1件: 13 13 |
866 | GABAPENTIN | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 5件: 6 6, 13, 19, 70, 298 |
867 | Gabapentine | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
868 | Gabapentine 300mg | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
869 | Gadobenate | 1件: Gadobenic acid Gadobenic acid | 2件: D04283
D04283
,
D08018
| - | - | 1件: 13 13 |
870 | Gadobenate Dimeglumine | 1件: Gadobenic acid Gadobenic acid | 2件: D04283
D04283
,
D08018
| - | - | 1件: 13 13 |
871 | GADOBUTROL | 1件: Gadobutrol Gadobutrol | 1件: D07420
D07420
| - | - | 3件: 13 13, 22, 46 |
872 | Gadolinium | 1件: Gadolinium Gadolinium | - | - | - | 6件: 13 13, 34, 46, 58, 65, 86 |
873 | Gadolinium-based contrast | 1件: Gadolinium Gadolinium | - | - | - | 1件: 13 13 |
874 | Gadopentetate | 1件: Gadopentetic acid Gadopentetic acid | 2件: D01707
D01707
,
D08006
| - | - | 2件: 13 13, 34 |
875 | Gadoteric acid | 1件: Gadoteric acid Gadoteric acid | 1件: D08007
D08007
| - | - | 1件: 13 13 |
876 | Gadoteridol | 1件: Gadoteridol Gadoteridol | 1件: D01137
D01137
| - | - | 1件: 13 13 |
877 | Gadovist | - | - | - | - | 2件: 13 13, 22 |
878 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 |
879 | Gadovist 1.0 mmol/ml Injektionslösung | - | - | - | - | 1件: 13 13 |
880 | Gamma-Tocopherol | 2件: Tocopherol Tocopherol, gamma-Tocopherol | 1件: D02332
D02332
| - | - | 1件: 13 13 |
881 | GBP | - | - | - | - | 1件: 13 13 |
882 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 |
883 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 |
884 | Genetic: Nicotine dependence | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 13 13 |
885 | Genotropin | - | - | - | - | 5件: 13 13, 78, 107, 187, 193 |
886 | GentleCath™ Air catheter | - | - | - | - | 1件: 13 13 |
887 | Gilenya | - | - | - | - | 3件: 2 2, 13, 14 |
888 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
889 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
890 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
891 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
892 | Gilenya / Imusera | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
893 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
894 | Gilenya® | - | - | - | - | 1件: 13 13 |
895 | Gileyna | - | - | - | - | 1件: 13 13 |
896 | Ginkgo | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 5件: 6 6, 13, 18, 47, 90 |
897 | Ginkgo biloba | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 4件: 13 13, 18, 47, 90 |
898 | Ginseng | 1件: Ginseng Ginseng | 1件: D06772
D06772
| - | - | 3件: 13 13, 46, 53 |
899 | GLA | - | - | - | - | 2件: 13 13, 19 |
900 | Glatiramer | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 4件: 2 2, 13, 96, 156 |
901 | GLATIRAMER ACETATE | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 3件: 13 13, 96, 156 |
902 | Glatiramer Acetate (Copaxone®) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 2件: 13 13, 156 |
903 | Glatiramer Acetate (DB) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
904 | Glatiramer Acetate (GA) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
905 | Glatiramer Acetate (GA) 40 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
906 | Glatiramer Acetate (GTR) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
907 | Glatiramer Acetate (OL) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
908 | Glatiramer acetate 150mg enteric coated tablets | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
909 | Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
910 | Glatiramer acetate 20 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
911 | Glatiramer acetate 20 mg, with mitoxantrone | 3件: Acetate Acetate, Glatiramer, Mitoxantrone | 3件: D02166
D02166
,
D04318
,
D08224
| 22件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 | 33件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
912 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
913 | Glatiramer acetate 40 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
914 | Glatiramer Acetate [GA] | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
915 | Glatiramer acetate injection with oral cetirizine hydrochloride | 3件: Acetate Acetate, Cetirizine, Glatiramer | 3件: D00664
D00664
,
D04318
,
D07662
| 21件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, HRH1 💬 | 35件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Calcium signaling pathway, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
916 | Glatiramer acetate with minocycline | 3件: Acetate Acetate, Glatiramer, Minocycline | 3件: D00850
D00850
,
D04318
,
D05045
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
917 | Glatiramer acetate, (Copaxone®) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
918 | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
919 | Glatiramer Acetate, N-Acetylcysteine | 3件: Acetate Acetate, Acetylcysteine, Glatiramer | 2件: D00221
D00221
,
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
920 | GLATIRAMER ACETATO | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
921 | GLATIRAMERO ACETATO | - | - | - | - | 1件: 13 13 |
922 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 |
923 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 15件: 2 2, 6, 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 |
924 | Glutamate and aspartate | - | - | - | - | 1件: 13 13 |
925 | Glycerol | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 5件: 6 6, 13, 79, 316, 317 |
926 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 13 13 |
927 | GNbAC1 | - | - | - | - | 1件: 13 13 |
928 | GNbAC1 Monoclonal Antibody | - | - | - | - | 1件: 13 13 |
929 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318 |
930 | Gold Nanocrystals | - | - | - | - | 3件: 2 2, 6, 13 |
931 | Granulocyte-colony stimulating factor (G-CSF) and prednisone | 2件: Filgrastim Filgrastim, Prednisone | 2件: D00473
D00473
,
D03235
| 2件: CSF3R CSF3R, NR3C1 💬 | 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 13 13 |
932 | Growth hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 13件: 2 2, 13, 19, 46, 78, 96, 107, 187, 191, 193, 195, 265, 299 |
933 | GSK1223249 | - | - | - | - | 2件: 2 2, 13 |
934 | GSK1841157 | - | - | - | - | 3件: 13 13, 35, 46 |
935 | GSK2018682 | - | - | - | - | 1件: 13 13 |
936 | GSK2018682 CD2 Capsule | - | - | - | - | 1件: 13 13 |
937 | GSK2018682 CD3 micronised Tablet | - | - | - | - | 1件: 13 13 |
938 | GSK2018682 CD3 non-micronised Tablet | - | - | - | - | 1件: 13 13 |
939 | GSK2018682 CD3 non-micronised Tablet in fed state | - | - | - | - | 1件: 13 13 |
940 | GSK239512 | - | - | - | - | 1件: 13 13 |
941 | GSK2395612 | - | - | - | - | 1件: 13 13 |
942 | GSK3888130B | - | - | - | - | 1件: 13 13 |
943 | GTR | - | - | - | - | 1件: 13 13 |
944 | GTR.ace | - | - | - | - | 1件: 13 13 |
945 | GUANABENZ | 1件: Guanabenz Guanabenz | 1件: D04375
D04375
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 2 2, 13 |
946 | GW-1000-02 | - | - | - | - | 1件: 13 13 |
947 | GYLENIA | - | - | - | - | 1件: 13 13 |
948 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 |
949 | GZ402668 | - | - | - | - | 1件: 13 13 |
950 | GZ402673 | - | - | - | - | 1件: 13 13 |
951 | H.P. Acthar Gel (repository corticotropin injection) | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
952 | H5G1.1-mAb | - | - | - | - | 3件: 13 13, 50, 62 |
953 | HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 14 |
954 | HB-adMSCs | 1件: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins | - | - | - | 7件: 2 2, 4, 6, 13, 46, 49, 113 |
955 | HBM9161 Injection | - | - | - | - | 1件: 13 13 |
956 | Helminth ova | - | - | - | - | 1件: 13 13 |
957 | Hematopoetic stem cell infusion | - | - | - | - | 1件: 13 13 |
958 | Hematopoietic Stem Cell Therapy | - | - | - | - | 1件: 13 13 |
959 | Hematopoietic Stem Cell Transplantation | - | - | - | - | 13件: 11 11, 13, 14, 19, 20, 35, 46, 49, 51, 65, 96, 234, 285 |
960 | Hematopoietic stem cell transplantation (HSCT) | - | - | - | - | 2件: 13 13, 60 |
961 | Heterologous booster | - | - | - | - | 1件: 13 13 |
962 | Hiberix | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 4件: 13 13, 61, 62, 66 |
963 | Hidrocloruro de fingolimod | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 14 |
964 | High Dose Aspirin (1300 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
965 | High Phenolic Extra Virgin Olive Oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
966 | High/Low Sodium Diet | - | - | - | - | 1件: 13 13 |
967 | Histamine | 1件: Histamine Histamine | 1件: D08040
D08040
| 4件: HRH1 HRH1, HRH2, HRH3, HRH4 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
968 | Histidine | 1件: Histidine Histidine | 1件: D00032
D00032
| - | - | 3件: 13 13, 169, 170 |
969 | HMR 1726D | - | - | - | - | 1件: 13 13 |
970 | HMR1726 | - | - | - | - | 1件: 13 13 |
971 | HMR1726D | - | - | - | - | 1件: 13 13 |
972 | Home based balance training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
973 | Homologous booster | - | - | - | - | 1件: 13 13 |
974 | Hookworm larvae | - | - | - | - | 1件: 13 13 |
975 | HP184 | - | - | - | - | 1件: 13 13 |
976 | HuL001 | - | - | - | - | 1件: 13 13 |
977 | Human anti-IL-12 IgG1 Mab | - | - | - | - | 1件: 13 13 |
978 | Human anti-IL-12 Mab | - | - | - | - | 1件: 13 13 |
979 | Human anti-LINGO-1 monoclonal antibody | - | - | - | - | 1件: 13 13 |
980 | Human autologous mesenchymal stem cells | - | - | - | - | 2件: 2 2, 13 |
981 | Human fetal-derived Neural Stem Cells (hNSCs) | - | - | - | - | 1件: 13 13 |
982 | Human interferon beta | 1件: Human interferon beta Human interferon beta | - | - | - | 2件: 13 13, 26 |
983 | Human interferon beta 1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
984 | Human interferon beta-1a and glatiramer acetate | 4件: Acetate Acetate, Glatiramer, Human interferon beta, Interferon beta-1a | 2件: D04318
D04318
,
D04554
| 22件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, IFNAR1, IFNAR2 💬 | 44件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
985 | HUMAN LEUCOCYTE INTERFERON-ALPHA | - | - | - | - | 1件: 13 13 |
986 | Human monoclonal antibody (CNTO 1275) to interleukin-12p40 | - | - | - | - | 1件: 13 13 |
987 | Human Neural Stem Cells | - | - | - | - | 2件: 2 2, 13 |
988 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
989 | Human recombinant growth hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 2件: 13 13, 299 |
990 | Human Umbilical Cord Mesenchymal Stem Cells | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 3件: 13 13, 96, 113 |
991 | HuMax-CD20 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 13 13, 46 |
992 | HYDROCHLOROTHIAZIDE | 1件: Hydrochlorothiazide Hydrochlorothiazide | 1件: D00340
D00340
| 1件: SLC12A3 SLC12A3 💬 | - | 4件: 13 13, 67, 225, 235 |
993 | Hydrogen | 1件: Hydrogen Hydrogen | - | - | - | 7件: 5 5, 6, 13, 17, 83, 97, 226 |
994 | Hydrogen peroxide | 2件: Hydrogen Hydrogen, Hydrogen peroxide | 1件: D00008
D00008
| - | - | 1件: 13 13 |
995 | Hydroxychloroquine | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: D08050
D08050
| - | - | 27件: 13 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 |
996 | Hydroxychloroquine and Indapamide | 2件: Hydroxychloroquine Hydroxychloroquine, Indapamide | 3件: D00345
D00345
,
D06401
,
D08050
| 1件: SLC12A3 SLC12A3 💬 | - | 1件: 13 13 |
997 | Hydroxytyrosol | 1件: Hydroxytyrosol Hydroxytyrosol | - | - | - | 1件: 13 13 |
998 | Hydroxyurea | 1件: Hydroxyurea Hydroxyurea | 1件: D00341
D00341
| 1件: RRM2 RRM2 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬 | 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 |
999 | Hyperimmune caprine serum against HIV lysate | - | - | - | - | 1件: 13 13 |
1000 | IBUDILAST | 1件: Ibudilast Ibudilast | 1件: D01385
D01385
| 8件: CYSLTR1 CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR 💬 | 16件: Apelin signaling pathway Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 2 2, 13 |
1001 | Ibuprofen | 1件: Ibuprofen Ibuprofen | 4件: D00126
D00126
,
D01122
,
D04490
,
D06606
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 7件: 13 13, 46, 65, 107, 113, 271, 299 |
1002 | Ibuprofen Sandoz 400 mg Filmtabletten | 1件: Ibuprofen Ibuprofen | 4件: D00126
D00126
,
D01122
,
D04490
,
D06606
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
1003 | Idebenone | 1件: Idebenone Idebenone | 1件: D01750
D01750
| - | - | 6件: 6 6, 8, 13, 18, 113, 302 |
1004 | IFA Incomplete Freund's Adjuvant | - | - | - | - | 1件: 13 13 |
1005 | IFN beta 1a 44 mcg TIW | - | - | - | - | 1件: 13 13 |
1006 | IFN beta-1a | - | - | - | - | 1件: 13 13 |
1007 | IFN ß-1a | - | - | - | - | 1件: 13 13 |
1008 | IFN-beta-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1009 | IFN-beta-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1010 | IFN-ß-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1011 | IFN-ß-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1012 | IL2 | - | - | - | - | 3件: 13 13, 60, 95 |
1013 | IM90838 | - | - | - | - | 3件: 13 13, 96, 97 |
1014 | Imatinib | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 |
1015 | IMATINIB MESILATE | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 3件: 13 13, 86, 88 |
1016 | Imatinib Mesylate | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 5件: 13 13, 28, 34, 51, 86 |
1017 | Immune globulin | - | - | - | - | 3件: 11 11, 13, 14 |
1018 | Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 13 13 |
1019 | Immunoadsorption | - | - | - | - | 2件: 13 13, 14 |
1020 | Immunoglobulin | - | - | - | - | 3件: 13 13, 14, 63 |
1021 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 |
1022 | IMMUNOSUPPRESSIVE AGENTS | - | - | - | - | 2件: 13 13, 50 |
1023 | Impact | - | - | - | - | 8件: 6 6, 13, 46, 50, 53, 96, 97, 299 |
1024 | IMS001 | - | - | - | - | 1件: 13 13 |
1025 | IMU-838 | - | - | - | - | 3件: 13 13, 96, 97 |
1026 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 |
1027 | IMU-838 (45 mg/day) | - | - | - | - | 1件: 13 13 |
1028 | IMU-838 tablets | - | - | - | - | 1件: 13 13 |
1029 | IMUREL | - | - | - | - | 4件: 13 13, 46, 96, 97 |
1030 | IncabotulinumtoxinA | - | - | - | - | 1件: 13 13 |
1031 | Incobotulinum Toxin A | - | - | - | - | 3件: 2 2, 6, 13 |
1032 | Indapamide | 1件: Indapamide Indapamide | 2件: D00345
D00345
,
D06401
| 1件: SLC12A3 SLC12A3 💬 | - | 1件: 13 13 |
1033 | INEBILIZUMAB | 1件: Inebilizumab Inebilizumab | 1件: D11757
D11757
| 1件: CD19 CD19 💬 | 5件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | 4件: 11 11, 13, 51, 300 |
1034 | INF beta-1a | - | - | - | - | 1件: 13 13 |
1035 | Influenza vaccine | - | - | - | - | 5件: 11 11, 13, 46, 51, 84 |
1036 | Inhaled Cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1037 | Injectable MS DMT | - | - | - | - | 1件: 13 13 |
1038 | Injection of autologous bone marrow derived mesenchymal stem cells | - | - | - | - | 1件: 13 13 |
1039 | Injection of cell free media | - | - | - | - | 1件: 13 13 |
1040 | INN COLECALCIFEROL | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
1041 | Inosine | 1件: Inosine Inosine | 1件: D00054
D00054
| - | - | 5件: 2 2, 6, 13, 17, 122 |
1042 | Insulin | - | - | - | - | 6件: 6 6, 13, 46, 75, 78, 299 |
1043 | INT131 | - | - | - | - | 1件: 13 13 |
1044 | Inteferone Beta-1A | - | - | - | - | 1件: 13 13 |
1045 | Interferon Beta | 1件: Human interferon beta Human interferon beta | - | - | - | 6件: 13 13, 20, 26, 50, 96, 97 |
1046 | INTERFERON BETA - 1A | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1047 | Interferon beta - 1a (IFN) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1048 | Interferon beta -1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1049 | Interferon Beta 1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1050 | Interferon Beta 1-A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1051 | Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1052 | Interferon Beta 1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1053 | Interferon beta 1a 30 ug IM once weekly | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1054 | Interferon Beta 1a pegilado | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1055 | Interferon beta 1a, oral doxycycline | 3件: Doxycycline Doxycycline, Human interferon beta, Interferon beta-1a | 6件: D00307
D00307
,
D02129
,
D03903
,
D03904
,
D04554
,
D07876
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1056 | Interferon beta 1B | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1057 | Interferon beta 1b (Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1058 | Interferon Beta Therapy | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1059 | Interferon beta treatment to add-on atorvastatin treatment | 2件: Atorvastatin Atorvastatin, Human interferon beta | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1060 | Interferon beta type 1a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1061 | Interferon beta-1 a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1062 | INTERFERON BETA-1A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 4件: 13 13, 26, 96, 97 |
1063 | Interferon beta-1a (Avonex) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1064 | INTERFERON BETA-1A (Avonex®) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1065 | Interferon beta-1a (current approved manufacturing process invloving FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1066 | Interferon beta-1a (new process, manufactured without FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1067 | Interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1068 | Interferon beta-1a (Rebif®) alone | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1069 | Interferon beta-1a 30 µg | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1070 | Interferon beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1071 | Interferon beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1072 | Interferon beta-1a FBS-free/HSA-free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1073 | Interferon beta-1a HSA+ biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1074 | Interferon beta-1a HSA-free biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1075 | Interferon beta-1a original | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1076 | Interferon Beta-1A Prefilled Syringe | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1077 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1078 | INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1079 | Interferon beta-1b (Betaferon, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1080 | Interferon beta-1b (Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1081 | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1082 | Interferon beta-1b (Betaferon®, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1083 | Interferon beta-1b (Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1084 | Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1085 | Interferon beta-1b (PF530, Betaferon) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1086 | Interferon beta-1b and Tacrolimus | 3件: Human interferon beta Human interferon beta, Interferon beta-1b, Tacrolimus | 3件: D00107
D00107
,
D00746
,
D08556
| 7件: IFNAR1 IFNAR1, IFNAR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 48件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Epstein-Barr virus infection, Glucagon signaling pathway, Glutamatergic synapse, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1087 | Interferon beta-1b group | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1088 | Interferon beta-1b, (Betaseron BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1089 | Interferon beta-1b, FRP about 6 weeks after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1090 | Interferon beta-1b, FRP within 15 days after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1091 | Interferon beta-1b/Atorvastatin group | 3件: Atorvastatin Atorvastatin, Human interferon beta, Interferon beta-1b | 4件: D00258
D00258
,
D00746
,
D00887
,
D07474
| 3件: HMGCR HMGCR, IFNAR1, IFNAR2 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Terpenoid backbone biosynthesis, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1092 | INTERFERON BETA1A | - | - | - | - | 1件: 13 13 |
1093 | Interferon or glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
1094 | Interferon ß-1a | - | - | - | - | 1件: 13 13 |
1095 | Interferon ß-1a 30 µg | - | - | - | - | 1件: 13 13 |
1096 | Interferon ß-1b | - | - | - | - | 1件: 13 13 |
1097 | Interferon-1beta (Betaseron, BAY86-5046) | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1098 | Interferon-Beta | 1件: Human interferon beta Human interferon beta | - | - | - | 2件: 13 13, 97 |
1099 | Interferon-beta (IFN-beta) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1100 | Interferon-beta 1a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1101 | Interferon-beta 1a FBS-free/HSA free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1102 | Interferon-beta 1a FBS-free/HSA-free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1103 | Interferon-beta 1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1104 | Interferon-beta 1b (Betaseron) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1105 | Interferon-beta [IFN-beta] | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1106 | Interferon-beta and human leukocyte Interferon-a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1107 | Interferon-beta-1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1108 | Interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 |
1109 | Interferon-beta-1a (Avonex) plus methylprednisolone | 3件: Human interferon beta Human interferon beta, Interferon beta-1a, Methylprednisolone | 7件: D00407
D00407
,
D00751
,
D00979
,
D04554
,
D05000
,
D05001
,
D05002
| 3件: IFNAR1 IFNAR1, IFNAR2, NR3C1 💬 | 19件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1110 | Interferon-beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1111 | Interferon-beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1112 | Interferon-beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1113 | Interferon-beta-1b (BETASERON, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1114 | Interferon-beta1 | - | - | - | - | 1件: 13 13 |
1115 | Interferon-ß | - | - | - | - | 1件: 13 13 |
1116 | Interferon-ß [IFN-ß] | - | - | - | - | 1件: 13 13 |
1117 | Interferon-ß-1 | - | - | - | - | 1件: 13 13 |
1118 | Interferon-ß-1a | - | - | - | - | 1件: 13 13 |
1119 | Interferon-ß-1b | - | - | - | - | 1件: 13 13 |
1120 | Interferone | - | - | - | - | 1件: 13 13 |
1121 | Interferone beta 1a | - | - | - | - | 1件: 13 13 |
1122 | INTERFERONE BETA 1B | - | - | - | - | 1件: 13 13 |
1123 | Interferone beta-1a | - | - | - | - | 1件: 13 13 |
1124 | Interferone Beta-1B | - | - | - | - | 1件: 13 13 |
1125 | Interferón beta 1a | - | - | - | - | 1件: 13 13 |
1126 | Interferón beta 1a pegilado | - | - | - | - | 1件: 13 13 |
1127 | Interferón Beta-1a pegilado | - | - | - | - | 1件: 13 13 |
1128 | Intradetrusor injection of Botulinum Toxin-A | - | - | - | - | 1件: 13 13 |
1129 | Intranasal Foralumab Solution | 1件: Foralumab Foralumab | - | - | - | 1件: 13 13 |
1130 | Intratect | - | - | - | - | 4件: 13 13, 14, 35, 65 |
1131 | Intrathecal administration of autologous MSC-NP | - | - | - | - | 1件: 13 13 |
1132 | Intrathecal methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 13 13 |
1133 | Intrathecal MSC-NP injection | - | - | - | - | 1件: 13 13 |
1134 | Intravenous (IV) infusions | - | - | - | - | 1件: 13 13 |
1135 | Intravenous Immunoglobulin | - | - | - | - | 8件: 13 13, 14, 35, 38, 39, 49, 51, 309 |
1136 | Intravenous injection of mesenchymal stem cells | - | - | - | - | 1件: 13 13 |
1137 | Intravenous Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 145 |
1138 | Intravenous steroid | - | - | - | - | 1件: 13 13 |
1139 | IPX056 | - | - | - | - | 1件: 13 13 |
1140 | IPX056 10 mg | - | - | - | - | 1件: 13 13 |
1141 | IPX056 20 mg | - | - | - | - | 1件: 13 13 |
1142 | IPX056 30 mg | - | - | - | - | 1件: 13 13 |
1143 | IPX056 35 mg | - | - | - | - | 1件: 13 13 |
1144 | IPX056 40 mg | - | - | - | - | 1件: 13 13 |
1145 | IPX056-10 mg | - | - | - | - | 1件: 13 13 |
1146 | IPX056-20 mg | - | - | - | - | 1件: 13 13 |
1147 | IPX056-25 mg | - | - | - | - | 1件: 13 13 |
1148 | IPX056-30 mg | - | - | - | - | 1件: 13 13 |
1149 | IPX056-35 mg | - | - | - | - | 1件: 13 13 |
1150 | IPX056-40 mg | - | - | - | - | 1件: 13 13 |
1151 | IR902 | - | - | - | - | 1件: 13 13 |
1152 | Iron oxide | 1件: Ferric oxide Ferric oxide | 1件: D04168
D04168
| - | - | 1件: 13 13 |
1153 | Irradiation | - | - | - | - | 1件: 13 13 |
1154 | IS (B cell depletion therapy) | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
1155 | IS (MMF or MPA) | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
1156 | IS (MTX) | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
1157 | ISENTRESS | 1件: Raltegravir Raltegravir | 1件: D06676
D06676
| - | - | 1件: 13 13 |
1158 | Isoxsuprine | 1件: Isoxsuprine Isoxsuprine | 1件: D08092
D08092
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1159 | Isoxsuprine Hydrochloride | 1件: Isoxsuprine Isoxsuprine | 1件: D08092
D08092
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1160 | IV methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1161 | IV methylprednisolone (steroids) | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1162 | IVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 8件: 11 11, 13, 14, 17, 35, 50, 51, 65 |
1163 | Ixazomib | 1件: Ixazomib Ixazomib | 1件: D10130
D10130
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 4件: 13 13, 16, 28, 51 |
1164 | Ixazomib (NINLARO®) capsules | 1件: Ixazomib Ixazomib | 1件: D10130
D10130
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 13 13 |
1165 | JM | - | - | - | - | 2件: 6 6, 13 |
1166 | JM-4 | - | - | - | - | 1件: 13 13 |
1167 | Kemstro | - | - | - | - | 1件: 13 13 |
1168 | Kepivance | 1件: Palifermin Palifermin | 1件: D05338
D05338
| 1件: FGFR2 FGFR2 💬 | 13件: Calcium signaling pathway Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells 💬 | 1件: 13 13 |
1169 | KEPPRA | 1件: Levetiracetam Levetiracetam | 1件: D00709
D00709
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 13 13 |
1170 | Keppra 250mg | 1件: Levetiracetam Levetiracetam | 1件: D00709
D00709
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 13 13 |
1171 | Keppra 500mg | 1件: Levetiracetam Levetiracetam | 1件: D00709
D00709
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 13 13 |
1172 | Keppra ® | 1件: Levetiracetam Levetiracetam | 1件: D00709
D00709
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 1件: 13 13 |
1173 | Kesimpta | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1174 | Kesimpta 20 mg Injektionslösung im Fertigpen | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1175 | Kesimpta 20 mg solution for injection in pre-filled pen | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1176 | KETAMINE | 1件: Ketamine Ketamine | 2件: D00711
D00711
,
D08098
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 6件: 6 6, 13, 70, 113, 156, 215 |
1177 | Ketoconazole | 1件: Ketoconazole Ketoconazole | 1件: D00351
D00351
| 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 3件: 8 8, 13, 75 |
1178 | Keyhole limpet hemocyanin | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 2件: 13 13, 46 |
1179 | Keyhole limpet hemocyanin (KLH) | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 |
1180 | Keyhole limpet hemocyanin (KLH) neo-antigen | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 |
1181 | Kirunal Fish Oil | 1件: Fish oil Fish oil | - | - | - | 1件: 13 13 |
1182 | KLH | - | - | - | - | 2件: 13 13, 65 |
1183 | L acetyl carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 1件: 13 13 |
1184 | L-000124467 | - | - | - | - | 2件: 13 13, 46 |
1185 | L-Carnitine | 1件: Levocarnitine Levocarnitine | 3件: D02030
D02030
,
D02176
,
D04713
| - | - | 7件: 13 13, 86, 96, 97, 265, 298, 316 |
1186 | L-Histidine | 1件: Histidine Histidine | 1件: D00032
D00032
| - | - | 1件: 13 13 |
1187 | L01BB04 | - | - | - | - | 1件: 13 13 |
1188 | L03 AB | - | - | - | - | 1件: 13 13 |
1189 | L03 AB 08 | - | - | - | - | 1件: 13 13 |
1190 | L03 AB07 | - | - | - | - | 1件: 13 13 |
1191 | L03AB13 | - | - | - | - | 1件: 13 13 |
1192 | L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 1件: 13 13 |
1193 | L04AA31 | - | - | - | - | 1件: 13 13 |
1194 | LA | - | - | - | - | 5件: 6 6, 13, 75, 76, 222 |
1195 | Lactose | 1件: Lactose Lactose | 2件: D00046
D00046
,
D03226
| - | - | 6件: 2 2, 6, 13, 97, 228, 310 |
1196 | Lactose monohydrate | 1件: Lactose Lactose | 2件: D00046
D00046
,
D03226
| - | - | 1件: 13 13 |
1197 | Lactulose | 1件: Lactulose Lactulose | 1件: D00352
D00352
| - | - | 3件: 13 13, 96, 291 |
1198 | Lamotrigine | 1件: Lamotrigine Lamotrigine | 1件: D00354
D00354
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 5件: 13 13, 34, 38, 114, 144 |
1199 | Lamotrigine extended release tablets | 1件: Lamotrigine Lamotrigine | 1件: D00354
D00354
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1200 | LAQUINIMOD | 1件: Laquinimod Laquinimod | - | - | - | 4件: 8 8, 13, 49, 96 |
1201 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1202 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1203 | Laquinimod 1.2 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1204 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1205 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1206 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1207 | Laquinimod Sodium (USAN) | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1208 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 |
1209 | Lemtrada | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 2件: 13 13, 65 |
1210 | LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
1211 | Lenograstim | 1件: Lenograstim Lenograstim | 1件: D03247
D03247
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 7件: 2 2, 13, 16, 18, 19, 57, 65 |
1212 | Levetiracetam | 1件: Levetiracetam Levetiracetam | 1件: D00709
D00709
| 1件: SV2A SV2A 💬 | 1件: ECM-receptor interaction ECM-receptor interaction 💬 | 5件: 2 2, 4, 6, 13, 307 |
1213 | Levitra | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 86 |
1214 | Levocarnil | - | - | - | - | 1件: 13 13 |
1215 | Levofolene | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 |
1216 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 |
1217 | LEVONORGESTREL | 1件: Levonorgestrel Levonorgestrel | 1件: D00950
D00950
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
1218 | LFB-R603 | - | - | - | - | 1件: 13 13 |
1219 | LFB-R603, TGTX1101 | - | - | - | - | 1件: 13 13 |
1220 | Lidocaine | 1件: Lidocaine Lidocaine | 3件: D00358
D00358
,
D02086
,
D08127
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 12件: 6 6, 13, 34, 46, 51, 70, 86, 107, 168, 226, 231, 256 |
1221 | Lidocaine patch 5% | 1件: Lidocaine Lidocaine | 3件: D00358
D00358
,
D02086
,
D08127
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1222 | Linoleic acid | 1件: Linoleic acid Linoleic acid | - | - | - | 4件: 2 2, 5, 13, 299 |
1223 | Linoleic Acid/Oleic Acid | 2件: Linoleic acid Linoleic acid, Oleic Acid | 1件: D02315
D02315
| - | - | 1件: 13 13 |
1224 | Liofen XL | - | - | - | - | 1件: 13 13 |
1225 | Liothyronine | 1件: Liothyronine Liothyronine | 2件: D01011
D01011
,
D08128
| 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 3件: 13 13, 210, 212 |
1226 | Liothyronine sodium | 1件: Liothyronine Liothyronine | 2件: D01011
D01011
,
D08128
| 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 13 13 |
1227 | Lipoic acid | 1件: Lipoic acid Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 5件: 2 2, 5, 13, 14, 20 |
1228 | Lipoic acid (LA) with fish oil and LA without fish oil | 2件: Fish oil Fish oil, Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 1件: 13 13 |
1229 | Lipoic acid and omega-3 fatty acids | 2件: Lipoic acid Lipoic acid, Omega-3 fatty acids | 2件: D00048
D00048
,
D00086
| - | - | 1件: 13 13 |
1230 | Lisdexamfetamine | 1件: Lisdexamfetamine Lisdexamfetamine | 1件: D08130
D08130
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1231 | Lisdexamfetamine sulfate | 2件: Lisdexamfetamine Lisdexamfetamine, Sulfate ion | 1件: D08130
D08130
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1232 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 |
1233 | LITHIUM CARBONATE | 2件: Carbonate ion Carbonate ion, Lithium carbonate | 1件: D00801
D00801
| - | - | 6件: 2 2, 13, 17, 18, 19, 127 |
1234 | Live Hookworm Larvae | - | - | - | - | 1件: 13 13 |
1235 | Live Necator americanus larvae | - | - | - | - | 1件: 13 13 |
1236 | Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI) | - | - | - | - | 1件: 13 13 |
1237 | Lodosyn | - | - | - | - | 1件: 13 13 |
1238 | Lokomat training | - | - | - | - | 1件: 13 13 |
1239 | Loperamide | 1件: Loperamide Loperamide | 3件: D00729
D00729
,
D07113
,
D08144
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 13 13, 97 |
1240 | Loratadine | 1件: Loratadine Loratadine | 1件: D00364
D00364
| 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 4件: 13 13, 46, 89, 98 |
1241 | LOU064 | - | - | - | - | 2件: 13 13, 53 |
1242 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
1243 | Low Dose Aspirin (162 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
1244 | Low dose cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1245 | Low immunogenic interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1246 | Lu AG06466 | - | - | - | - | 1件: 13 13 |
1247 | LUBIPROSTONE | 1件: Lubiprostone Lubiprostone | 1件: D04790
D04790
| 1件: CLCN2 CLCN2 💬 | 1件: Mineral absorption Mineral absorption 💬 | 4件: 6 6, 13, 290, 299 |
1248 | Lumbar Puncture | - | - | - | - | 6件: 6 6, 13, 19, 96, 97, 127 |
1249 | Lutein | 1件: Lutein Lutein | - | - | - | 3件: 13 13, 90, 164 |
1250 | LUTENYL | - | - | - | - | 1件: 13 13 |
1251 | LY2127399 | - | - | - | - | 3件: 13 13, 46, 49 |
1252 | LY248686 | - | - | - | - | 1件: 13 13 |
1253 | Lysine | 1件: Lysine Lysine | 1件: D02304
D02304
| - | - | 4件: 13 13, 97, 228, 299 |
1254 | M2951 | - | - | - | - | 3件: 13 13, 46, 49 |
1255 | MABCAMPATH | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 2件: 13 13, 60 |
1256 | MABCAMPATH 10 mg/ml concentrado para solución para perfusión | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
1257 | MabCampath ® | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
1258 | MabCampath-1h | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
1259 | MabCampath® | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 13 13 |
1260 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
1261 | MabThera (Rituximab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 4件: 13 13, 46, 49, 53 |
1262 | Mabthera or biosimilar rituximab product | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1263 | Mabthera® | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 6件: 13 13, 35, 43, 44, 46, 93 |
1264 | Magnesium | 1件: Magnesium Magnesium | - | - | - | 19件: 3 3, 6, 11, 13, 15, 46, 64, 70, 93, 97, 166, 225, 235, 256, 284, 291, 296, 297, 298 |
1265 | Magnetic Resonance Imaging | - | - | - | - | 7件: 6 6, 13, 19, 22, 34, 205, 299 |
1266 | Maltodextrin | 1件: Maltodextrin Maltodextrin | 1件: D02329
D02329
| - | - | 4件: 6 6, 13, 96, 97 |
1267 | Maltodextrin fiber supplement | 1件: Maltodextrin Maltodextrin | 1件: D02329
D02329
| - | - | 1件: 13 13 |
1268 | Mangafodipir | 1件: Mangafodipir Mangafodipir | 1件: D08262
D08262
| - | - | 2件: 13 13, 58 |
1269 | Mangafodipir (Teslascan) | 1件: Mangafodipir Mangafodipir | 1件: D08262
D08262
| - | - | 1件: 13 13 |
1270 | Mannitol | 1件: Mannitol Mannitol | 1件: D00062
D00062
| - | - | 7件: 6 6, 13, 28, 60, 96, 113, 299 |
1271 | Mannose | 1件: Mannose Mannose | - | - | - | 2件: 13 13, 256 |
1272 | MANTADAN*20CPR 100MG | - | - | - | - | 1件: 13 13 |
1273 | Marijuana | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1274 | Masitinb mesylate | - | - | - | - | 1件: 13 13 |
1275 | MASITINIB | 1件: Masitinib Masitinib | 1件: D10229
D10229
| 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 6件: 2 2, 5, 6, 13, 46, 96 |
1276 | Masitinib mesilate | 1件: Masitinib Masitinib | 1件: D10229
D10229
| 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 13 |
1277 | MASITINIB MESYLATE | 1件: Masitinib Masitinib | 1件: D10229
D10229
| 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 6件: 2 2, 5, 6, 13, 46, 96 |
1278 | Mastinib | - | - | - | - | 1件: 13 13 |
1279 | MAVENCLAD | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1280 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1281 | MAVENCLAD 10 mg tablets | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1282 | Mavenclad tabletter 10 mg | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1283 | Mavenclad® | 1件: Cladribine Cladribine | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
1284 | Mayzent | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1285 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1286 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1287 | Mayzent 2 mg film-coated tablets | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1288 | Mayzent 2 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1289 | MBP peptide | - | - | - | - | 1件: 13 13 |
1290 | MBP8298 | - | - | - | - | 1件: 13 13 |
1291 | MBP8298 Synthetic Peptide | - | - | - | - | 1件: 13 13 |
1292 | MD1003 | - | - | - | - | 5件: 2 2, 10, 13, 14, 20 |
1293 | MD1003 100mg capsule | - | - | - | - | 1件: 13 13 |
1294 | MEDI-551 | - | - | - | - | 2件: 13 13, 51 |
1295 | MEDI-551 100 MG-IV | - | - | - | - | 1件: 13 13 |
1296 | MEDI-551 30 MG-IV | - | - | - | - | 1件: 13 13 |
1297 | MEDI-551 300 MG-SC | - | - | - | - | 1件: 13 13 |
1298 | MEDI-551 60 MG-SC | - | - | - | - | 1件: 13 13 |
1299 | MEDI-551 600 MG-IV | - | - | - | - | 1件: 13 13 |
1300 | Medical Marijuana | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1301 | Medication Event Monitoring System (MEMS) | - | - | - | - | 1件: 13 13 |
1302 | Medrol | - | - | - | - | 4件: 13 13, 46, 56, 222 |
1303 | Megadose oral methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1304 | Melatonin | 1件: Melatonin Melatonin | 1件: D08170
D08170
| 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 12件: 6 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202 |
1305 | Melphalan | 1件: Melphalan Melphalan | 1件: D00369
D00369
| - | - | 15件: 11 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 |
1306 | Memantine | 1件: Memantine Memantine | 2件: D04905
D04905
,
D08174
| 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 7件: 2 2, 6, 8, 13, 49, 127, 205 |
1307 | Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) | - | - | - | - | 1件: 13 13 |
1308 | Menitorix | - | - | - | - | 1件: 13 13 |
1309 | Menveo | 1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | - | - | - | 6件: 11 11, 13, 61, 62, 66, 222 |
1310 | Mesenchymal stem cells | - | - | - | - | 11件: 2 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
1311 | Mesenchymal stem cells (MSC) | - | - | - | - | 3件: 2 2, 13, 96 |
1312 | Mesenchymal stem cells (MSCs) | - | - | - | - | 3件: 13 13, 36, 96 |
1313 | Mesenchymal stem/stromal cells | - | - | - | - | 1件: 13 13 |
1314 | Mesna | 1件: Coenzyme M Coenzyme M | - | - | - | 11件: 11 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164 |
1315 | Metabolic fatigue | - | - | - | - | 1件: 13 13 |
1316 | Metex | - | - | - | - | 2件: 13 13, 46 |
1317 | Metformin | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
1318 | Methelphenidate | - | - | - | - | 1件: 13 13 |
1319 | Methotrexat | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 4件: 13 13, 46, 50, 96 |
1320 | Methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
1321 | Methyl B12 | - | - | - | - | 1件: 13 13 |
1322 | Methyl folate | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 13 13 |
1323 | Methyl Prednisolonate | - | - | - | - | 1件: 13 13 |
1324 | Methyloprednisolone | - | - | - | - | 1件: 13 13 |
1325 | Methylphenidate | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 7件: 6 6, 13, 34, 84, 113, 179, 206 |
1326 | METHYLPHENIDATE HYDROCHLORIDE | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 2件: 6 6, 13 |
1327 | Methylphenidate modified release | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1328 | Methylphenidate modified release 20 mg | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1329 | Methylphenidate modified release 30 mg | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1330 | Methylphenidate modified release 40 mg | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1331 | Methylprednisolon | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 4件: 13 13, 14, 51, 66 |
1332 | Methylprednisolon-21-hydrogensuccinat, Natriumsalz | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1333 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
1334 | Methylprednisolone (drug) | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1335 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1336 | Methylprednisolone hemisuccinate | 2件: Methylprednisolone Methylprednisolone, Methylprednisolone hemisuccinate | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1337 | Methylprednisolone IV | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1338 | Methylprednisolone PO | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1339 | METHYLPREDNISOLONE SODIUM HEMISUCCINATE | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 97 |
1340 | METHYLPREDNISOLONE SODIUM SUCCINATE | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 6件: 13 13, 46, 49, 50, 51, 211 |
1341 | Methylprednisolone succinate | 2件: Methylprednisolone Methylprednisolone, Methylprednisolone hemisuccinate | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1342 | METILPREDNISOLONE | - | - | - | - | 6件: 11 11, 13, 53, 56, 63, 300 |
1343 | Metilprednisolone sodio succinato | - | - | - | - | 3件: 13 13, 14, 56 |
1344 | Mg | - | - | - | - | 4件: 6 6, 13, 51, 111 |
1345 | Microgynon | - | - | - | - | 2件: 13 13, 51 |
1346 | Microgynon® | - | - | - | - | 1件: 13 13 |
1347 | Micropirin | - | - | - | - | 1件: 13 13 |
1348 | Midazolam | 1件: Midazolam Midazolam | 3件: D00550
D00550
,
D00696
,
D05028
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 12件: 2 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298 |
1349 | Mild dose cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1350 | Mineral boost (magnesium) | 1件: Magnesium Magnesium | - | - | - | 1件: 13 13 |
1351 | Minocycline | 1件: Minocycline Minocycline | 2件: D00850
D00850
,
D05045
| - | - | 13件: 2 2, 6, 8, 13, 46, 85, 90, 94, 162, 201, 206, 280, 299 |
1352 | Minocycline 100 mg Film-coated Tablets | 1件: Minocycline Minocycline | 2件: D00850
D00850
,
D05045
| - | - | 1件: 13 13 |
1353 | Minocycline 100mg | 1件: Minocycline Minocycline | 2件: D00850
D00850
,
D05045
| - | - | 1件: 13 13 |
1354 | Minocycline Hydrochloride | 1件: Minocycline Minocycline | 2件: D00850
D00850
,
D05045
| - | - | 4件: 13 13, 201, 206, 299 |
1355 | Mirabegron | 1件: Mirabegron Mirabegron | 1件: D09535
D09535
| 1件: ADRB3 ADRB3 💬 | 8件: Calcium signaling pathway Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway 💬 | 4件: 6 6, 13, 53, 226 |
1356 | MIS416 | - | - | - | - | 1件: 13 13 |
1357 | MitoQ | - | - | - | - | 3件: 6 6, 13, 97 |
1358 | Mitoquinone | 1件: Mitoquinone Mitoquinone | - | - | - | 1件: 13 13 |
1359 | Mitoxantrone | 1件: Mitoxantrone Mitoxantrone | 2件: D02166
D02166
,
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
1360 | MK0812 | - | - | - | - | 2件: 13 13, 46 |
1361 | MLN1202 | - | - | - | - | 1件: 13 13 |
1362 | MMF | - | - | - | - | 15件: 13 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 162, 222, 224, 226, 299 |
1363 | MODAFINIL | 1件: Modafinil Modafinil | 1件: D01832
D01832
| - | - | 4件: 6 6, 13, 49, 93 |
1364 | Moderna mRNA-1273 | - | - | - | - | 5件: 13 13, 35, 46, 49, 51 |
1365 | MOG peptide | - | - | - | - | 1件: 13 13 |
1366 | MONITOR | 1件: Methamidophos Methamidophos | - | - | - | 20件: 2 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300 |
1367 | Monoclonal antibody M-T412 | - | - | - | - | 1件: 13 13 |
1368 | Monomethyl fumarate | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: D11492
D11492
| - | - | 1件: 13 13 |
1369 | Monomethyl fumarate 190 mg | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: D11492
D11492
| - | - | 1件: 13 13 |
1370 | Montelukast | 1件: Montelukast Montelukast | 2件: D00529
D00529
,
D08229
| 1件: CYSLTR1 CYSLTR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 8件: 6 6, 13, 46, 61, 63, 85, 98, 228 |
1371 | MOR103 | - | - | - | - | 2件: 13 13, 46 |
1372 | Most recent vaccine to seasonal influenza | - | - | - | - | 1件: 13 13 |
1373 | MPA | - | - | - | - | 6件: 13 13, 35, 46, 49, 51, 60 |
1374 | MRI | - | - | - | - | 5件: 13 13, 70, 78, 85, 278 |
1375 | MRI contrast-enhancing preparations | - | - | - | - | 1件: 13 13 |
1376 | MRNA COVID-19 vaccine | - | - | - | - | 1件: 13 13 |
1377 | MSC2015 | - | - | - | - | 1件: 13 13 |
1378 | MSC2304479A | - | - | - | - | 1件: 13 13 |
1379 | MSC2304480A | - | - | - | - | 1件: 13 13 |
1380 | MSC2304481A | - | - | - | - | 1件: 13 13 |
1381 | MSC2304482A | - | - | - | - | 1件: 13 13 |
1382 | MSC2358825A | - | - | - | - | 1件: 13 13 |
1383 | MSC2364447C | - | - | - | - | 2件: 13 13, 49 |
1384 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 |
1385 | MSC2491529A | - | - | - | - | 1件: 13 13 |
1386 | MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1387 | MSmonitor, a self-management/education program with e-health interventions | - | - | - | - | 1件: 13 13 |
1388 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 |
1389 | MT-1303 | - | - | - | - | 3件: 13 13, 96, 97 |
1390 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 |
1391 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 |
1392 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 |
1393 | MT-1303-FormA | - | - | - | - | 1件: 13 13 |
1394 | MT-1303-FormB | - | - | - | - | 1件: 13 13 |
1395 | MT-1303-High | - | - | - | - | 1件: 13 13 |
1396 | MT-1303-Low | - | - | - | - | 1件: 13 13 |
1397 | MT-1303-Middle | - | - | - | - | 1件: 13 13 |
1398 | MTX | - | - | - | - | 14件: 13 13, 35, 40, 46, 49, 50, 51, 60, 84, 96, 97, 107, 162, 271 |
1399 | Multiferon | - | - | - | - | 1件: 13 13 |
1400 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | - | - | - | - | 1件: 13 13 |
1401 | Mutagrip | - | - | - | - | 2件: 11 11, 13 |
1402 | MyBETAapp | - | - | - | - | 1件: 13 13 |
1403 | Mycophenolate | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
1404 | Mycophenolate mofetil | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
1405 | Mycophenolate mofetil (CellCept) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 2件: 11 11, 13 |
1406 | Mycophenolate mofetil (MMF) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 7件: 13 13, 49, 51, 60, 65, 66, 222 |
1407 | Méthylprednisolone | - | - | - | - | 1件: 13 13 |
1408 | Méthylprednisolone Mylan | - | - | - | - | 1件: 13 13 |
1409 | N acetylcysteine | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 1件: 13 13 |
1410 | N-acetyl Cysteine | 1件: Cysteine Cysteine | 2件: D00026
D00026
,
D02326
| - | - | 7件: 13 13, 19, 34, 85, 88, 296, 310 |
1411 | N-Acetylcysteine | 1件: Acetylcysteine Acetylcysteine | 1件: D00221
D00221
| - | - | 11件: 6 6, 13, 19, 20, 49, 58, 85, 111, 164, 299, 337 |
1412 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 |
1413 | N. MENINGITIDIS GROUP W135 OLIGOSACCHARIDE CONJUGATED CRM197 | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 13 13 |
1414 | N.a. | - | - | - | - | 10件: 3 3, 6, 8, 13, 46, 96, 97, 240, 256, 271 |
1415 | N02BG10 | - | - | - | - | 1件: 13 13 |
1416 | N03AX12 | - | - | - | - | 1件: 13 13 |
1417 | N06DX01 | - | - | - | - | 1件: 13 13 |
1418 | Na18F | - | - | - | - | 1件: 13 13 |
1419 | NABILONE | 1件: Nabilone Nabilone | 1件: D05099
D05099
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 6 6, 13 |
1420 | Nabiximols | 1件: Nabiximols Nabiximols | 1件: D09317
D09317
| - | - | 1件: 13 13 |
1421 | Nabiximols - Sativex | 2件: Dronabinol Dronabinol, Nabiximols | 2件: D00306
D00306
,
D09317
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
1422 | Naltrexone | 1件: Naltrexone Naltrexone | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 12件: 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 |
1423 | Namisol | - | - | - | - | 2件: 13 13, 298 |
1424 | Nanocort | - | - | - | - | 3件: 13 13, 46, 97 |
1425 | Nanocurcumin | - | - | - | - | 2件: 13 13, 271 |
1426 | Naproxen | 1件: Naproxen Naproxen | 1件: D00118
D00118
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 4件: 13 13, 46, 107, 271 |
1427 | NATALIZUMAB | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 5件: 13 13, 15, 25, 46, 96 |
1428 | Natalizumab (BG00002) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1429 | Natalizumab (NTZ) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1430 | Natalizumab (Tysabri) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1431 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1432 | Natalizumab for IV Infusion | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1433 | Natalizumab for Subcutaneous Injection | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1434 | Natalizumab Injection [Tysabri] | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1435 | Natalizumab IV | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1436 | Natalizumab SC | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1437 | Natalizumab treatment | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1438 | NBI-5788 | - | - | - | - | 1件: 13 13 |
1439 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 |
1440 | Nd | - | - | - | - | 6件: 2 2, 6, 13, 46, 51, 97 |
1441 | Nebido | - | - | - | - | 1件: 13 13 |
1442 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 2件: Testosterone Testosterone, Testosterone undecanoate | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
1443 | Necator americanus | - | - | - | - | 1件: 13 13 |
1444 | NeoRecormon | - | - | - | - | 2件: 13 13, 18 |
1445 | Neramexane | 1件: Neramexane Neramexane | - | - | - | 1件: 13 13 |
1446 | Neramexane mesylate | 1件: Neramexane Neramexane | - | - | - | 1件: 13 13 |
1447 | Nerispirdine | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
1448 | Nerispirdine (HP184) | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
1449 | Nerispirdine hydrochloride | 1件: Nerispirdine Nerispirdine | - | - | - | 1件: 13 13 |
1450 | NEUPOGEN | - | - | - | - | 4件: 13 13, 28, 51, 285 |
1451 | NEUROASPIS PLP10® | - | - | - | - | 1件: 13 13 |
1452 | Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV | - | - | - | - | 1件: 13 13 |
1453 | NEURONTIN | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1454 | Neurontin 300 mg hard capsule | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1455 | NeuroVax | - | - | - | - | 1件: 13 13 |
1456 | NeuroVax 300ug/mL Dose for IM Injection | - | - | - | - | 1件: 13 13 |
1457 | New Formulation of rebif - human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1458 | Niacinamide | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 4件: 5 5, 6, 13, 67 |
1459 | NICOTINE | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 3件: 6 6, 13, 84 |
1460 | Ninlaro | 1件: Ixazomib Ixazomib | 1件: D10130
D10130
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 2件: 13 13, 61 |
1461 | Nintendo Wii Fit Balance Board | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1462 | NIRS after bosentan administration | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1463 | NIRS baseline | - | - | - | - | 1件: 13 13 |
1464 | Nitrofurantoin | 1件: Nitrofurantoin Nitrofurantoin | 1件: D00439
D00439
| - | - | 1件: 13 13 |
1465 | Nivolumab | 1件: Nivolumab Nivolumab | 1件: D10316
D10316
| 1件: PDCD1 PDCD1 💬 | 3件: Cell adhesion molecules Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬 | 12件: 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
1466 | NO | - | - | - | - | 12件: 6 6, 13, 46, 58, 62, 86, 96, 97, 222, 226, 299, 321 |
1467 | Nomegestrol | 1件: Nomegestrol Nomegestrol | 1件: D07222
D07222
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
1468 | Nomegestrol acetate | 3件: Acetate Acetate, Nomegestrol, Nomegestrol acetate | 2件: D07222
D07222
,
D08281
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
1469 | Non applicabile | - | - | - | - | 4件: 13 13, 49, 51, 256 |
1470 | Non-pegylated interferon | - | - | - | - | 1件: 13 13 |
1471 | Norethindrone | 1件: Norethisterone Norethisterone | 2件: D00182
D00182
,
D00953
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 4件: 13 13, 46, 49, 299 |
1472 | Normal Saline | - | - | - | - | 18件: 6 6, 13, 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 271, 276, 296, 299 |
1473 | Normal Saline for Injection | - | - | - | - | 1件: 13 13 |
1474 | Novantrone | 1件: Mitoxantrone Mitoxantrone | 2件: D02166
D02166
,
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
1475 | NOVANTRONE*INF 2MG/ML 5ML | 1件: Mitoxantrone Mitoxantrone | 2件: D02166
D02166
,
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
1476 | Novartis Pharmaceuticals Corporation | - | - | - | - | 1件: 13 13 |
1477 | NOVATREX | - | - | - | - | 1件: 13 13 |
1478 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 |
1479 | NT-KO-003 | - | - | - | - | 1件: 13 13 |
1480 | NU100 | - | - | - | - | 1件: 13 13 |
1481 | Null | - | - | - | - | 16件: 6 6, 13, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
1482 | NurOwn (MSC-NTF cells) | - | - | - | - | 1件: 13 13 |
1483 | NVF233 | - | - | - | - | 1件: 13 13 |
1484 | OCH-NCNP1 | - | - | - | - | 1件: 13 13 |
1485 | Oclelizumab | - | - | - | - | 1件: 13 13 |
1486 | OCR | - | - | - | - | 1件: 13 13 |
1487 | OCRELIZUMAB | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 46, 49 |
1488 | Ocrelizumab (CinnaGen, Iran) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1489 | Ocrelizumab (Roche, Switzerland) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1490 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1491 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1492 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1493 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1494 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1495 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1496 | Ocrelizumab at home | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1497 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1498 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1499 | Ocrelizumab IV | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1500 | Ocrelizumab SC | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1501 | OCREVUS | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1502 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1503 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 |
1504 | Octagam | - | - | - | - | 2件: 13 13, 65 |
1505 | Octagam 5% | - | - | - | - | 2件: 13 13, 65 |
1506 | Octagam 50 mg/ml | - | - | - | - | 1件: 13 13 |
1507 | Ocufolin | - | - | - | - | 1件: 13 13 |
1508 | OFATUMUMAB | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 35, 46 |
1509 | Ofatumumab 100 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1510 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1511 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1512 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1513 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1514 | Ofatumumab 700 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1515 | Ofatumumab subcutaneous injection | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1516 | Oleic Acid | 1件: Oleic Acid Oleic Acid | 1件: D02315
D02315
| - | - | 2件: 13 13, 299 |
1517 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 |
1518 | Olesoxime (TRO19622) | 1件: TRO19622 TRO19622 | - | - | - | 1件: 13 13 |
1519 | Olive | 1件: Olea europaea leaf Olea europaea leaf | - | - | - | 3件: 13 13, 49, 53 |
1520 | Olive oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 3件: 13 13, 49, 53 |
1521 | OMB 157 | - | - | - | - | 1件: 13 13 |
1522 | OMB157 | - | - | - | - | 1件: 13 13 |
1523 | OMB157G | - | - | - | - | 1件: 13 13 |
1524 | Omega 3 | - | - | - | - | 3件: 13 13, 53, 299 |
1525 | Omega 3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 13 13 |
1526 | Omega-3 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 7件: 13 13, 46, 49, 66, 79, 96, 299 |
1527 | Omega-3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 13 13, 79 |
1528 | Omeprazole | 1件: Omeprazole Omeprazole | 4件: D00455
D00455
,
D01207
,
D05259
,
D05261
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 16件: 6 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
1529 | OnabotulinumtoxinA | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 3件: 6 6, 13, 226 |
1530 | ONO-4641 | - | - | - | - | 1件: 13 13 |
1531 | ONO-4641/ MSC2430913A | - | - | - | - | 1件: 13 13 |
1532 | ONO-4641/MSC2430913A | - | - | - | - | 1件: 13 13 |
1533 | Opicinumab | 1件: Opicinumab Opicinumab | 1件: D11767
D11767
| 1件: LINGO1 LINGO1 💬 | - | 1件: 13 13 |
1534 | Optical coherence tomography (OCT) | - | - | - | - | 1件: 13 13 |
1535 | Optical coherence tomography angiography (OCTA) | - | - | - | - | 1件: 13 13 |
1536 | Oral corticosteroids | - | - | - | - | 4件: 13 13, 46, 97, 171 |
1537 | Oral lipoic acid (LA) | 1件: Lipoic acid Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 1件: 13 13 |
1538 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1539 | Oral THC | - | - | - | - | 1件: 13 13 |
1540 | Orelabrutinib | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 3件: 13 13, 61, 63 |
1541 | ORY2001 | - | - | - | - | 1件: 13 13 |
1542 | OS440 | - | - | - | - | 1件: 13 13 |
1543 | Other analgesics and antipyretics | - | - | - | - | 1件: 13 13 |
1544 | Other disease-modifying therapy | - | - | - | - | 1件: 13 13 |
1545 | Other H1 antagonist | - | - | - | - | 1件: 13 13 |
1546 | OTHER NERVOUS SYSTEM DRUGS | - | - | - | - | 2件: 6 6, 13 |
1547 | Other: anxiety | - | - | - | - | 1件: 13 13 |
1548 | Other: At-home natalizumab treated MS patient | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1549 | Other: Balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 3件: 6 6, 13, 299 |
1550 | Other: Balance exercise program using exoskeleton device | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1551 | Other: Balance exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1552 | Other: Balance Trainer Balance Exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1553 | Other: Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
1554 | Other: Berg Balance Scale | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
1555 | Other: Caffeine | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1556 | Other: Cardiopulmonary evaluation | - | - | - | - | 1件: 13 13 |
1557 | Other: Cawthorne Cooksey exercises | - | - | - | - | 1件: 13 13 |
1558 | Other: Classic, progressive endurance training | - | - | - | - | 1件: 13 13 |
1559 | Other: CoDuSe balance training and step square exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1560 | Other: conventional balance training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1561 | Other: Core stability | - | - | - | - | 1件: 13 13 |
1562 | Other: Covid-19 vaccine | - | - | - | - | 1件: 13 13 |
1563 | Other: Determination of calcium intake by a dietician interview | 1件: Calcium Calcium | - | - | - | 2件: 13 13, 46 |
1564 | Other: DMT withdrawal | - | - | - | - | 1件: 13 13 |
1565 | Other: Dual Task Performance | - | - | - | - | 1件: 13 13 |
1566 | Other: Dynamic Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1567 | Other: Dynamic balance walking training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1568 | Other: Evaluation of degree chronic fatigue. | - | - | - | - | 1件: 13 13 |
1569 | Other: Exercise intervention | - | - | - | - | 2件: 13 13, 18 |
1570 | Other: Exposure to methylprednisolone during pregnancy | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1571 | Other: fatigue | - | - | - | - | 1件: 13 13 |
1572 | Other: Fear of falling | - | - | - | - | 1件: 13 13 |
1573 | Other: fingolimod | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1574 | Other: Four Square Step Test | - | - | - | - | 2件: 6 6, 13 |
1575 | Other: Functional mobility | - | - | - | - | 2件: 6 6, 13 |
1576 | Other: Functional Reach Test | - | - | - | - | 2件: 6 6, 13 |
1577 | Other: Group balance training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1578 | Other: Histamine | 1件: Histamine Histamine | 1件: D08040
D08040
| 4件: HRH1 HRH1, HRH2, HRH3, HRH4 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
1579 | Other: Hydrogen peroxide | 2件: Hydrogen Hydrogen, Hydrogen peroxide | 1件: D00008
D00008
| - | - | 1件: 13 13 |
1580 | Other: Imaging | - | - | - | - | 1件: 13 13 |
1581 | Other: Incontinence Severity | - | - | - | - | 1件: 13 13 |
1582 | Other: Intrathecal saline injection | - | - | - | - | 1件: 13 13 |
1583 | Other: Kesimpta | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1584 | Other: Laboratory Biomarker Analysis | - | - | - | - | 21件: 11 11, 13, 14, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 205, 232, 283, 284, 285, 298, 331 |
1585 | Other: Liberation therapy | - | - | - | - | 1件: 13 13 |
1586 | Other: mitoxantrone - immunomodulator | 1件: Mitoxantrone Mitoxantrone | 2件: D02166
D02166
,
D08224
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 |
1587 | Other: Modified paleolithic diet | - | - | - | - | 1件: 13 13 |
1588 | Other: MSCs | - | - | - | - | 1件: 13 13 |
1589 | Other: myBETAapp | - | - | - | - | 1件: 13 13 |
1590 | Other: Natalizumab | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1591 | Other: Natalizumab discontinuation | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1592 | Other: NBT-NM108 (0 g/day) | - | - | - | - | 1件: 13 13 |
1593 | Other: Neuromuscular evaluation | - | - | - | - | 1件: 13 13 |
1594 | Other: Nintendo Wii Fit Balance exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1595 | Other: No device | - | - | - | - | 1件: 13 13 |
1596 | Other: NO intervention | - | - | - | - | 4件: 13 13, 70, 96, 97 |
1597 | Other: No MSDMDs therapy (control) | - | - | - | - | 1件: 13 13 |
1598 | Other: No Treatment Arm | - | - | - | - | 1件: 13 13 |
1599 | Other: Non Impact Aerobics | - | - | - | - | 1件: 13 13 |
1600 | Other: normal saline | - | - | - | - | 4件: 13 13, 222, 226, 280 |
1601 | Other: Observation of Ocrelizumab as Treatment in RRMS Patients | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1602 | Other: Observational Control | - | - | - | - | 1件: 13 13 |
1603 | Other: Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1604 | Other: Ofatumumab | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1605 | Other: One-leg Stance Test | - | - | - | - | 1件: 13 13 |
1606 | Other: Other: Disease modifying therapies (DMT) | - | - | - | - | 1件: 13 13 |
1607 | Other: pain | - | - | - | - | 1件: 13 13 |
1608 | Other: Passive : lecture series | - | - | - | - | 1件: 13 13 |
1609 | Other: PEAK | - | - | - | - | 1件: 13 13 |
1610 | Other: Peanut Butter | 1件: Peanut Peanut | - | - | - | 1件: 13 13 |
1611 | Other: Periodized exercise training | - | - | - | - | 1件: 13 13 |
1612 | Other: plasticity-based computerized cognitive remediation program | - | - | - | - | 1件: 13 13 |
1613 | Other: PNF | - | - | - | - | 1件: 13 13 |
1614 | Other: Position Sense | - | - | - | - | 1件: 13 13 |
1615 | Other: Progressive exercise | - | - | - | - | 1件: 13 13 |
1616 | Other: propensity score | - | - | - | - | 1件: 13 13 |
1617 | Other: PSP | - | - | - | - | 1件: 13 13 |
1618 | Other: QALCIMUM questionnaire | - | - | - | - | 2件: 13 13, 46 |
1619 | Other: Questionnaires | - | - | - | - | 5件: 6 6, 13, 41, 93, 96 |
1620 | Other: Rhythmic Auditory Stimulation (RAS) | - | - | - | - | 2件: 6 6, 13 |
1621 | Other: Siponimod | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1622 | Other: specifically design 6 month resistance training program | - | - | - | - | 1件: 13 13 |
1623 | Other: Spinning grp | - | - | - | - | 1件: 13 13 |
1624 | Other: standard of care | - | - | - | - | 7件: 13 13, 49, 64, 85, 96, 245, 246 |
1625 | Other: Static Balance Test | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1626 | Other: Strength training | - | - | - | - | 1件: 13 13 |
1627 | Other: Supervised physical therapy | - | - | - | - | 1件: 13 13 |
1628 | Other: Timed Up an Go Test | - | - | - | - | 1件: 13 13 |
1629 | Other: Training groupe | - | - | - | - | 1件: 13 13 |
1630 | Other: Trunk impairment | - | - | - | - | 1件: 13 13 |
1631 | Other: Trunk position sense | - | - | - | - | 1件: 13 13 |
1632 | Other: USPIO MRI - Gadolinium MRI | 1件: Gadolinium Gadolinium | - | - | - | 1件: 13 13 |
1633 | Other: Vestibular habituation exercises | - | - | - | - | 1件: 13 13 |
1634 | Other: Vestibular rehabilitation: balance and eye movement exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
1635 | Other: Virtual reality group | - | - | - | - | 1件: 13 13 |
1636 | Other: Vitamin K | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 1件: 13 13 |
1637 | Other: Vitamin K Cream | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 1件: 13 13 |
1638 | Other: Withdrawal of dalfampridine-ER 10mg | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
1639 | OVASTAT | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
1640 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
1641 | Ovastat 5000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
1642 | Oxcarbazepine | 1件: Oxcarbazepine Oxcarbazepine | 1件: D00533
D00533
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1643 | Oxine | 1件: Oxyquinoline Oxyquinoline | 1件: D05321
D05321
| - | - | 1件: 13 13 |
1644 | Oxybutynin | 1件: Oxybutynin Oxybutynin | 2件: D00465
D00465
,
D00722
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 3件: 6 6, 13, 53 |
1645 | Oxybutynin hydrochloride | 1件: Oxybutynin Oxybutynin | 2件: D00465
D00465
,
D00722
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 2件: 6 6, 13 |
1646 | Oxycodone | 1件: Oxycodone Oxycodone | 3件: D03783
D03783
,
D05312
,
D05462
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 7件: 6 6, 13, 46, 70, 226, 231, 298 |
1647 | Oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 20件: 6 6, 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 168, 193, 226, 271, 294, 299, 330 |
1648 | Ozanimod | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 96, 97 |
1649 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1650 | Ozanimod 1 mg | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1651 | Ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1652 | Ozanimod HCL | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1653 | Ozanimod hydrochloride | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 96, 97 |
1654 | Paired associative stimulation (PAS) | - | - | - | - | 1件: 13 13 |
1655 | Palifermin | 1件: Palifermin Palifermin | 1件: D05338
D05338
| 1件: FGFR2 FGFR2 💬 | 13件: Calcium signaling pathway Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells 💬 | 5件: 13 13, 36, 38, 39, 65 |
1656 | Pantoprazole | 1件: Pantoprazole Pantoprazole | 2件: D02593
D02593
,
D05353
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 13 13, 65 |
1657 | PARACETAMOL | 1件: Acetaminophen Acetaminophen | 1件: D00217
D00217
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 6件: 3 3, 6, 13, 35, 46, 49 |
1658 | Paracetamolo 500 mg | - | - | - | - | 1件: 13 13 |
1659 | Paroxetine | 1件: Paroxetine Paroxetine | 4件: D02260
D02260
,
D02362
,
D05374
,
D05375
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 4件: 6 6, 13, 46, 85 |
1660 | Part A: 100 mg/mL GSK2618960 | - | - | - | - | 1件: 13 13 |
1661 | Part B: Dose of GSK2618960 decided from Part A | - | - | - | - | 1件: 13 13 |
1662 | Part C: Dose of GSK2618960 decided from Part A and B | - | - | - | - | 1件: 13 13 |
1663 | PAS | - | - | - | - | 1件: 13 13 |
1664 | PAT | - | - | - | - | 3件: 6 6, 13, 160 |
1665 | PB006 | - | - | - | - | 1件: 13 13 |
1666 | PCV | - | - | - | - | 1件: 13 13 |
1667 | Peanut | 1件: Peanut Peanut | - | - | - | 1件: 13 13 |
1668 | PEG | - | - | - | - | 12件: 6 6, 13, 41, 46, 65, 78, 96, 97, 140, 144, 240, 299 |
1669 | PEG-liposomal Prednisolone Sodium Phosphate | 2件: Phosphate ion Phosphate ion, Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 97 |
1670 | PEGINTERFERON BETA-1A | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1671 | Peginterferone beta 1a | - | - | - | - | 1件: 13 13 |
1672 | PEGINTERFERONE BETA-1A | - | - | - | - | 1件: 13 13 |
1673 | PEGINTERFERONE LAMBDA-1A | - | - | - | - | 1件: 13 13 |
1674 | PEGylated Intereron Beta-1a | - | - | - | - | 1件: 13 13 |
1675 | PEGylated Interferon Beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1676 | Pending | - | - | - | - | 6件: 13 13, 19, 96, 97, 113, 302 |
1677 | Peripheral Blood Stem Cell Transplantation | - | - | - | - | 12件: 11 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285, 286 |
1678 | Personalized extended interval dosing of natalizumab | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
1679 | Pertussis vaccine | 1件: Pertussis vaccine Pertussis vaccine | 1件: D06514
D06514
| - | - | 2件: 13 13, 46 |
1680 | PET with 11C-Flumazenil | 1件: Flumazenil Flumazenil | 1件: D00697
D00697
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 |
1681 | PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714 | - | - | - | - | 1件: 13 13 |
1682 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 |
1683 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 |
1684 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 |
1685 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR | 1件: Lysine Lysine | 1件: D02304
D02304
| - | - | 1件: 13 13 |
1686 | Phenytoin | 1件: Phenytoin Phenytoin | 2件: D00512
D00512
,
D02103
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1687 | Phosphate | 1件: Phosphate ion Phosphate ion | - | - | - | 33件: 2 2, 3, 6, 11, 12, 13, 15, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299 |
1688 | PI-2301 | - | - | - | - | 1件: 13 13 |
1689 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 2件: D00945
D00945
,
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
1690 | PIPE-307 | - | - | - | - | 1件: 13 13 |
1691 | Pirfenidone | 1件: Pirfenidone Pirfenidone | 1件: D01583
D01583
| 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
1692 | PIXANTRONE | 1件: Pixantrone Pixantrone | 1件: D05522
D05522
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 2件: 11 11, 13 |
1693 | PL 04515/0127 | - | - | - | - | 1件: 13 13 |
1694 | PL 12762/0049 | - | - | - | - | 1件: 13 13 |
1695 | Placebo | - | - | - | - | 27件: 3 3, 5, 6, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
1696 | Plasma exchange | - | - | - | - | 5件: 13 13, 43, 44, 64, 222 |
1697 | Platelet transfusion | - | - | - | - | 1件: 13 13 |
1698 | Platform | - | - | - | - | 1件: 13 13 |
1699 | PLEDIGRY | - | - | - | - | 1件: 13 13 |
1700 | Plegridy | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1701 | Plegridy (peginterferon beta-1a), Biogen Idec Ltd | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1702 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1703 | Plegridy 125 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1704 | Plegridy 63 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1705 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 |
1706 | Plovamer acetate | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
1707 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
1708 | Plovamer acetate 10 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
1709 | Plovamer acetate 20 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
1710 | Plovamer acetate 3 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 |
1711 | PLP | - | - | - | - | 1件: 13 13 |
1712 | PLP peptide | - | - | - | - | 1件: 13 13 |
1713 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) | - | - | - | - | 2件: 13 13, 14 |
1714 | Pneumococcal polysaccharide vaccine | - | - | - | - | 3件: 13 13, 46, 222 |
1715 | Pneumovax II | - | - | - | - | 1件: 13 13 |
1716 | PNU-215062 sodium salt | - | - | - | - | 1件: 13 13 |
1717 | PO | - | - | - | - | 1件: 13 13 |
1718 | Polyphenon E | - | - | - | - | 2件: 13 13, 36 |
1719 | PONESIMOD | 1件: Ponesimod Ponesimod | 1件: D11215
D11215
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1720 | Ponesimod 10 mg | 1件: Ponesimod Ponesimod | 1件: D11215
D11215
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1721 | Ponesimod 20 mg | 1件: Ponesimod Ponesimod | 1件: D11215
D11215
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1722 | Ponesimod 40 mg | 1件: Ponesimod Ponesimod | 1件: D11215
D11215
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1723 | Pravastatin | 1件: Pravastatin Pravastatin | 2件: D00893
D00893
,
D08410
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 9件: 13 13, 46, 49, 67, 79, 96, 164, 265, 333 |
1724 | PRD806998 | - | - | - | - | 1件: 13 13 |
1725 | Prebiotics (Prebiotin Prebiotic Fiber Stick Pac) | - | - | - | - | 1件: 13 13 |
1726 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 43件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
1727 | PREDNISOLONE SODIUM PHOSPHATE | 2件: Phosphate ion Phosphate ion, Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 3 3, 13, 97 |
1728 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
1729 | Pregabalin | 1件: Pregabalin Pregabalin | 1件: D02716
D02716
| 4件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4 💬 | 7件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway 💬 | 5件: 13 13, 36, 46, 70, 298 |
1730 | Prepulsid | - | - | - | - | 1件: 13 13 |
1731 | Prevenar 13 | 1件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen | - | - | - | 5件: 13 13, 14, 46, 96, 222 |
1732 | PRN2246 | - | - | - | - | 2件: 11 11, 13 |
1733 | Probiotics (Visbiome®) | - | - | - | - | 1件: 13 13 |
1734 | Prohance (Gadoteridol) | 1件: Gadoteridol Gadoteridol | 1件: D01137
D01137
| - | - | 1件: 13 13 |
1735 | Prolonged-release Fampridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
1736 | Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal) | - | - | - | - | 1件: 13 13 |
1737 | Provigil | 1件: Modafinil Modafinil | 1件: D01832
D01832
| - | - | 2件: 13 13, 113 |
1738 | Provigil (modafinil) | 1件: Modafinil Modafinil | 1件: D01832
D01832
| - | - | 1件: 13 13 |
1739 | PRUCALOPRIDE | 1件: Prucalopride Prucalopride | 1件: D09205
D09205
| 1件: HTR4 HTR4 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway 💬 | 3件: 13 13, 51, 96 |
1740 | PTL201 | - | - | - | - | 1件: 13 13 |
1741 | PV | - | - | - | - | 3件: 13 13, 97, 215 |
1742 | Quadrivalent influenza vaccine | - | - | - | - | 1件: 13 13 |
1743 | Quality of life | - | - | - | - | 1件: 13 13 |
1744 | Quetiapine | 1件: Quetiapine Quetiapine | 2件: D00458
D00458
,
D08456
| 2件: DRD2 DRD2, HTR2A 💬 | 11件: Alcoholism Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway 💬 | 2件: 6 6, 13 |
1745 | Quinidina | 1件: Quinidine Quinidine | 4件: D00642
D00642
,
D00643
,
D02272
,
D08458
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1746 | Quinidina sulfato | 1件: Quinidine Quinidine | 4件: D00642
D00642
,
D00643
,
D02272
,
D08458
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1747 | Quinidine | 1件: Quinidine Quinidine | 4件: D00642
D00642
,
D00643
,
D02272
,
D08458
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 3件: 2 2, 8, 13 |
1748 | Quinidine Sulfate | 2件: Quinidine Quinidine, Sulfate ion | 4件: D00642
D00642
,
D00643
,
D02272
,
D08458
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
1749 | R lipoic acid | 1件: Lipoic acid Lipoic acid | 2件: D00048
D00048
,
D00086
| - | - | 1件: 13 13 |
1750 | Rabbit | 1件: Rabbit Rabbit | - | - | - | 8件: 11 11, 13, 49, 51, 60, 65, 96, 285 |
1751 | Rabbit anti-human thymocyte immunoglobulin | 2件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Rabbit | - | - | - | 2件: 13 13, 96 |
1752 | RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN | 1件: Rabbit Rabbit | - | - | - | 2件: 13 13, 60 |
1753 | Radiation therapy | - | - | - | - | 3件: 13 13, 284, 285 |
1754 | Radiation: Gadopentetate Dimeglumine | 1件: Gadopentetic acid Gadopentetic acid | 2件: D01707
D01707
,
D08006
| - | - | 2件: 13 13, 34 |
1755 | Ralenova | - | - | - | - | 1件: 13 13 |
1756 | Raltegravir | 1件: Raltegravir Raltegravir | 1件: D06676
D06676
| - | - | 4件: 13 13, 26, 93, 265 |
1757 | Ramatroban | 1件: Ramatroban Ramatroban | 1件: D01128
D01128
| 2件: PTGDR PTGDR, TBXA2R 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation 💬 | 1件: 13 13 |
1758 | Ranitidine | 1件: Ranitidine Ranitidine | 2件: D00422
D00422
,
D00673
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 65 |
1759 | Raptiva | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 9件: 11 11, 13, 37, 46, 49, 53, 61, 95, 96 |
1760 | Raptiva 100 mg/ml powder and solvent for solution for injection | 1件: Efalizumab Efalizumab | 1件: D03959
D03959
| 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 7件: 11 11, 13, 46, 53, 61, 95, 96 |
1761 | RAS | - | - | - | - | 4件: 6 6, 13, 58, 66 |
1762 | RATG | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 4件: 13 13, 51, 60, 285 |
1763 | RAVULIZUMAB | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
1764 | RC18 160 mg | - | - | - | - | 2件: 13 13, 53 |
1765 | RC18 160mg | - | - | - | - | 3件: 11 11, 13, 66 |
1766 | RC18 240mg | - | - | - | - | 2件: 13 13, 66 |
1767 | REBIF | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1768 | Rebif (IFN beta-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1769 | Rebif (IFN ß-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1770 | Rebif (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1771 | Rebif (Interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1772 | Rebif (interferon beta-1a), Merck Serono Europe Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1773 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1774 | Rebif 22 | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1775 | Rebif 22 micrograms | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1776 | Rebif 22 y 44 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1777 | Rebif 22® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1778 | Rebif 44 | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1779 | REBIF 44 microgramos solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1780 | REBIF 44 microgramos solución inyectable en jeringa precargada | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1781 | Rebif 44 micrograms | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1782 | Rebif 44 micrograms solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1783 | Rebif 44 micrograms solution for injection in pre-filled syringe | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1784 | Rebif 44 µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1785 | Rebif 44® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1786 | Rebif 8,8 µg, Rebif 22µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1787 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1788 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack. | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1789 | Rebif New Formulation + ibuprofen PRN | 1件: Ibuprofen Ibuprofen | 4件: D00126
D00126
,
D01122
,
D04490
,
D06606
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
1790 | Rebif New Formulation + prophylactic Ibuprofen | 1件: Ibuprofen Ibuprofen | 4件: D00126
D00126
,
D01122
,
D04490
,
D06606
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 |
1791 | Rebif New Formulation 44mcg multidose cartridge | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1792 | Rebif New Formulation Non Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1793 | Rebif New Formulation Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1794 | REBIF SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1795 | REBIF SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1796 | REBIF*SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1797 | REBIF*SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1798 | Rebif® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1799 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1800 | Rebif® New Formulation | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1801 | Rebif® New Formulation (IFN-beta-1a, RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1802 | Rebif® new formulation (RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1803 | Rebif® New Formulation (RNF) using RebiSmartTM | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1804 | Recombinant human alpha B-crystallin | - | - | - | - | 1件: 13 13 |
1805 | Recombinant Human Erythropoietin | 1件: Erythropoietin Erythropoietin | 1件: D03231
D03231
| 1件: EPOR EPOR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 13 13 |
1806 | Recombinant human IFN beta | - | - | - | - | 1件: 13 13 |
1807 | Recombinant human interferon beta | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 |
1808 | Recombinant humanized anti-alpha 4 integrin antibody | - | - | - | - | 1件: 13 13 |
1809 | RECOMBINANT INTERFERON BE | - | - | - | - | 1件: 13 13 |
1810 | RECOMBINANT INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1811 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN | 1件: Iron polymaltose Iron polymaltose | - | - | - | 2件: 11 11, 13 |
1812 | Release | 1件: Manganese citrate Manganese citrate | - | - | - | 12件: 6 6, 8, 13, 46, 65, 78, 81, 96, 97, 206, 226, 299 |
1813 | Remibrutinib | - | - | - | - | 2件: 13 13, 53 |
1814 | Repetitive transcranial magnetic stimulation (rTMS) | - | - | - | - | 1件: 13 13 |
1815 | Repository corticotropin injection | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 5件: 2 2, 13, 46, 84, 222 |
1816 | Researchmanager program | - | - | - | - | 1件: 13 13 |
1817 | REVAXIS | - | - | - | - | 1件: 13 13 |
1818 | RG2077 (CTLA4-IgG4m) | - | - | - | - | 1件: 13 13 |
1819 | RHB-104 | - | - | - | - | 2件: 13 13, 96 |
1820 | RhEPO | - | - | - | - | 1件: 13 13 |
1821 | RhIFN beta-1b | - | - | - | - | 1件: 13 13 |
1822 | RhIGF-1 (CEP-151) | - | - | - | - | 1件: 13 13 |
1823 | RHIgM22 | - | - | - | - | 1件: 13 13 |
1824 | RhuMab 2H7 | - | - | - | - | 3件: 13 13, 46, 49 |
1825 | RhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 4件: 13 13, 46, 56, 96 |
1826 | RhumAb to IL-17A igG1-k-class | - | - | - | - | 1件: 13 13 |
1827 | RHuPH20 | - | - | - | - | 2件: 13 13, 14 |
1828 | Riboflavin | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 8件: 13 13, 38, 46, 96, 97, 162, 168, 265 |
1829 | Rifampin | 1件: Rifampicin Rifampicin | 1件: D00211
D00211
| - | - | 5件: 6 6, 13, 84, 86, 299 |
1830 | RILUTEK | 1件: Riluzole Riluzole | 1件: D00775
D00775
| 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 3件: 2 2, 13, 203 |
1831 | RILUZOLE | 1件: Riluzole Riluzole | 1件: D00775
D00775
| 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
1832 | RimabotulinumtoxinB | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: D02735
D02735
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1833 | RIPK1 inhibitor | - | - | - | - | 1件: 13 13 |
1834 | Ritalin | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 2件: 6 6, 13 |
1835 | Ritalin LA 20mg capsules | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1836 | Ritalin LA 30mg capsules | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1837 | Ritalin LA 40mg capsules | 1件: Methylphenidate Methylphenidate | 2件: D01296
D01296
,
D04999
| 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 |
1838 | Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
1839 | Rituximab Infusion | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 13 13, 222 |
1840 | Rituximab IT | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1841 | Rituximab IV | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1842 | Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1843 | Rivastigmin | - | - | - | - | 1件: 13 13 |
1844 | RIVASTIGMINE | 1件: Rivastigmine Rivastigmine | 2件: D02558
D02558
,
D03822
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 3件: 5 5, 6, 13 |
1845 | Rivastigmine transdermal patch | 1件: Rivastigmine Rivastigmine | 2件: D02558
D02558
,
D03822
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 2件: 6 6, 13 |
1846 | RNF | - | - | - | - | 1件: 13 13 |
1847 | RNS60 | - | - | - | - | 2件: 2 2, 13 |
1848 | RNS60 125 ml | - | - | - | - | 1件: 13 13 |
1849 | RNS60 250 ml | - | - | - | - | 1件: 13 13 |
1850 | Ro 496-4913/F03 | - | - | - | - | 2件: 13 13, 46 |
1851 | Ro 496-4913/F07 | - | - | - | - | 1件: 13 13 |
1852 | RO0506997 | - | - | - | - | 2件: 13 13, 46 |
1853 | RO4964913 | - | - | - | - | 1件: 13 13 |
1854 | RO4964913 F07 | - | - | - | - | 1件: 13 13 |
1855 | RO4964913/F03 | - | - | - | - | 1件: 13 13 |
1856 | RO4964913/F07 | - | - | - | - | 1件: 13 13 |
1857 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 |
1858 | RO5333787 | - | - | - | - | 2件: 11 11, 13 |
1859 | RO7010939 | - | - | - | - | 2件: 13 13, 46 |
1860 | Rolipram | 1件: Rolipram Rolipram | 1件: D01783
D01783
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 8 8, 13 |
1861 | RPC-1063 | - | - | - | - | 1件: 13 13 |
1862 | RPC1063 | - | - | - | - | 3件: 13 13, 96, 97 |
1863 | RTL1000 (recombinant T cell receptor ligand) | - | - | - | - | 1件: 13 13 |
1864 | Ruxience | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1865 | RYAH-Medtech Inhaler | - | - | - | - | 5件: 2 2, 6, 13, 96, 97 |
1866 | S-Warfarin | 2件: (S)-Warfarin (S)-Warfarin, Warfarin | 3件: D00564
D00564
,
D01280
,
D08682
| 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 13 13 |
1867 | SA237 | - | - | - | - | 1件: 13 13 |
1868 | Saline | - | - | - | - | 10件: 6 6, 13, 17, 53, 67, 78, 86, 97, 168, 299 |
1869 | SAR339658 | - | - | - | - | 2件: 13 13, 97 |
1870 | SAR441344 | - | - | - | - | 3件: 13 13, 49, 53 |
1871 | SAR441344 IV | - | - | - | - | 2件: 13 13, 49 |
1872 | SAR441344 SC | - | - | - | - | 2件: 13 13, 49 |
1873 | SAR442168 | - | - | - | - | 2件: 11 11, 13 |
1874 | SARS-COV-2 mRNA Vaccine | 1件: CVnCoV CVnCoV | - | - | - | 1件: 13 13 |
1875 | Sativex | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 2 2, 13 |
1876 | Sativex 2,7mg/2,5 mg Solucion para pulverizacion bucal | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
1877 | Sativex Oromucosal Spray | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
1878 | Sativex Oromucosal Spray (non-marketed) | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
1879 | Sativex® | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
1880 | SATRALIZUMAB | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 11 11, 13 |
1881 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1882 | Satralizumab (120 mg/vial) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1883 | Satralizumab (120mg/vial) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1884 | Satralizumab (r-INN) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1885 | Satralizumab (RO5333787/Enspryng /SA237) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1886 | Satralizumab (RO5333787/Enspryng/SA237) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1887 | Satralizumab (RO5333787/SA237) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1888 | Satrazlizumab (RO5333787/ Enspryng /SA237) | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
1889 | SB-683699 | - | - | - | - | 1件: 13 13 |
1890 | SB683699 | - | - | - | - | 1件: 13 13 |
1891 | SC interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1892 | SC interferon beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1893 | SC Peginterferon beta-1a | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: D10483
D10483
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1894 | SCLEROLYM | - | - | - | - | 1件: 13 13 |
1895 | SCM | - | - | - | - | 1件: 13 13 |
1896 | SCM-010 | - | - | - | - | 1件: 13 13 |
1897 | Seasonal influenza vaccine | - | - | - | - | 2件: 13 13, 46 |
1898 | Seasonal Quadrivalent influenza vaccine | - | - | - | - | 1件: 13 13 |
1899 | Second-generation fumaric acid | 1件: Fumaric acid Fumaric acid | 1件: D02308
D02308
| - | - | 1件: 13 13 |
1900 | SECUKINUMAB | 1件: Secukinumab Secukinumab | 1件: D09967
D09967
| 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 8件: 13 13, 37, 41, 46, 107, 160, 269, 271 |
1901 | See Intervention Description) | - | - | - | - | 1件: 13 13 |
1902 | Selenium | 1件: Selenium Selenium | - | - | - | 4件: 13 13, 96, 278, 298 |
1903 | Sendoxan | - | - | - | - | 2件: 13 13, 43 |
1904 | Sendoxane | - | - | - | - | 1件: 13 13 |
1905 | Serum containing Avonex | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1906 | Serum Free Avonex | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1907 | SH U 555 C | - | - | - | - | 1件: 13 13 |
1908 | Sham Transcranial Direct Current Stimulation (tDCS) | - | - | - | - | 1件: 13 13 |
1909 | Short-course Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
1910 | Silodyx | 1件: Silodosin Silodosin | 1件: D01965
D01965
| 1件: ADRA1A ADRA1A 💬 | 7件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1911 | Simethicone | 1件: Simethicone Simethicone | 1件: D05841
D05841
| - | - | 2件: 13 13, 96 |
1912 | SimvaHEXAL® 40 mg Filmtabletten | - | - | - | - | 1件: 13 13 |
1913 | Simvastatin | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 21件: 6 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 |
1914 | Simvastatin 40 mg film-coated tablets | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1915 | Simvastatin Alternova | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1916 | Simvastatin in relapsing remitting multiple sclerosis | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1917 | Simvastatina | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1918 | Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1919 | Simvastatine | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 6 6, 13, 288 |
1920 | Simvastatine Sandoz 40 mg filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1921 | Simvastatine Sandoz 40mg deelbare filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: D00434
D00434
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
1922 | Single-point cane (SPC) | - | - | - | - | 1件: 13 13 |
1923 | Single-pulse transcranial magnetic stimulation (spTMS) | - | - | - | - | 1件: 13 13 |
1924 | Single-use autoinjector | - | - | - | - | 1件: 13 13 |
1925 | Single-use autoinjector with a prefilled liquid Avonex syringe | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
1926 | Sinvastatina Sandoz 40 mg comprimidos revestidos por película | - | - | - | - | 1件: 13 13 |
1927 | Siponimob | - | - | - | - | 1件: 13 13 |
1928 | SIPONIMOD | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
1929 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1930 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
1931 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
1932 | Siponimod 1 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1933 | Siponimod 1 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
1934 | Siponimod 2 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1935 | Siponimod 2 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
1936 | SIPONIMOD FUMARIC ACID | 2件: Fumaric acid Fumaric acid, Siponimod | 2件: D02308
D02308
,
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
1937 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 36件: 6 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
1938 | Sivatin | - | - | - | - | 1件: 13 13 |
1939 | Sivatin 40 mg film-coated tablets | - | - | - | - | 1件: 13 13 |
1940 | Sivelestat | 1件: Sivelestat Sivelestat | 1件: D03788
D03788
| 1件: ELANE ELANE 💬 | 3件: Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Systemic lupus erythematosus, Transcriptional misregulation in cancer 💬 | 3件: 13 13, 85, 96 |
1941 | Sleep assessment | - | - | - | - | 1件: 13 13 |
1942 | SMderpept | - | - | - | - | 1件: 13 13 |
1943 | Smoked Cannabis | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1944 | Sodium chlorid | - | - | - | - | 1件: 13 13 |
1945 | Sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 21件: 6 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 168, 193, 227, 228, 271, 288, 299 |
1946 | Sodium Chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 3件: 11 11, 13, 228 |
1947 | Solifenacin | 1件: Solifenacin Solifenacin | 2件: D01269
D01269
,
D08522
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 3件: 6 6, 13, 53 |
1948 | Solifenacin Succinate | 1件: Solifenacin Solifenacin | 2件: D01269
D01269
,
D08522
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
1949 | SOLIRIS | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 11 11, 13, 14, 61, 62, 109, 222 |
1950 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 |
1951 | SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML | - | - | - | - | 3件: 13 13, 14, 53 |
1952 | Solu-Medrol | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: D05000
D05000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 7件: 13 13, 49, 50, 51, 53, 97, 211 |
1953 | SOLU-MODERIN 1 g | - | - | - | - | 1件: 13 13 |
1954 | SoluMedrol | - | - | - | - | 1件: 13 13 |
1955 | Solumedrol IM 125mg/2ml | - | - | - | - | 1件: 13 13 |
1956 | Somatorelin | 1件: Somatorelin Somatorelin | 1件: D08523
D08523
| 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 78 |
1957 | SPARC0921 | - | - | - | - | 1件: 13 13 |
1958 | Spikevax | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: D12114
D12114
| - | - | 1件: 13 13 |
1959 | Spiropent | - | - | - | - | 2件: 6 6, 13 |
1960 | SR-fampridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
1961 | Ss-interferon | - | - | - | - | 1件: 13 13 |
1962 | Standard gadolinium contrast | 1件: Gadolinium Gadolinium | - | - | - | 1件: 13 13 |
1963 | Standard interval dosing | - | - | - | - | 1件: 13 13 |
1964 | Standard MS DMT | - | - | - | - | 1件: 13 13 |
1965 | Standard MS DMTs | - | - | - | - | 1件: 13 13 |
1966 | Standard of Care | - | - | - | - | 10件: 6 6, 13, 46, 49, 51, 63, 64, 79, 171, 271 |
1967 | Standard treatment with a conventional drug | - | - | - | - | 1件: 13 13 |
1968 | Standardized cannabis extract | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
1969 | Statin | - | - | - | - | 1件: 13 13 |
1970 | Stem Cell Transplantation | - | - | - | - | 13件: 13 13, 19, 20, 46, 51, 60, 62, 65, 90, 125, 164, 234, 326 |
1971 | Study Drug | - | - | - | - | 2件: 6 6, 13 |
1972 | SUB0750MIG | - | - | - | - | 1件: 13 13 |
1973 | SUB175614 | - | - | - | - | 1件: 13 13 |
1974 | SUB22282 | - | - | - | - | 1件: 13 13 |
1975 | Sublingual tizanidine 12 mg | 1件: Tizanidine Tizanidine | 2件: D00776
D00776
,
D08611
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1976 | Sulfate | 1件: Sulfate ion Sulfate ion | - | - | - | 27件: 2 2, 3, 6, 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 218, 222, 226, 265, 296, 297, 299 |
1977 | Sunphenon | - | - | - | - | 2件: 13 13, 113 |
1978 | Sunphenon EGCG | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 3件: 13 13, 17, 113 |
1979 | Sunphenon EGCg TM | - | - | - | - | 1件: 13 13 |
1980 | Suspension media | - | - | - | - | 1件: 13 13 |
1981 | Sustained-release oral dalfampridine | 1件: Dalfampridine Dalfampridine | 1件: D04127
D04127
| 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 |
1982 | Suvorexant | 1件: Suvorexant Suvorexant | 1件: D10082
D10082
| 2件: HCRTR1 HCRTR1, HCRTR2 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 5 5, 6, 13 |
1983 | Syngeneic Bone Marrow Transplantation | - | - | - | - | 3件: 11 11, 13, 14 |
1984 | T cell vaccination | - | - | - | - | 1件: 13 13 |
1985 | T-Cell Vaccination | - | - | - | - | 1件: 13 13 |
1986 | Tachipirina | - | - | - | - | 2件: 13 13, 53 |
1987 | TACHIPIRINA - 500 MG COMPRESSE20 COMPRESSE | - | - | - | - | 2件: 13 13, 53 |
1988 | Tachipirina CPR 500mg | - | - | - | - | 1件: 13 13 |
1989 | TACI-Fc5 | 1件: Atacicept Atacicept | 1件: D09704
D09704
| 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 13 13, 46, 49 |
1990 | Tacrolimus | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
1991 | Tanakan | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 13 13 |
1992 | Tarenflurbil | 1件: Tarenflurbil Tarenflurbil | 1件: D09010
D09010
| 4件: APH1A APH1A, NCSTN, PSEN1, PSENEN 💬 | 6件: Alzheimer disease Alzheimer disease, Human papillomavirus infection, Neurotrophin signaling pathway, Notch signaling pathway, Pathways of neurodegeneration - multiple diseases, Wnt signaling pathway 💬 | 1件: 13 13 |
1993 | Targretin | 1件: Bexarotene Bexarotene | 1件: D03106
D03106
| 3件: RXRA RXRA, RXRB, RXRG 💬 | 17件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 13 13 |
1994 | Taurine | 1件: Taurine Taurine | 1件: D00047
D00047
| - | - | 2件: 13 13, 337 |
1995 | TAUROURSODEOXYCHOLIC ACID | 1件: Tauroursodeoxycholic acid Tauroursodeoxycholic acid | 1件: D11836
D11836
| - | - | 4件: 2 2, 13, 93, 299 |
1996 | TCD after bosentan administration | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
1997 | TCD baseline | - | - | - | - | 1件: 13 13 |
1998 | Tcelna | - | - | - | - | 1件: 13 13 |
1999 | TECFIDERA | - | - | - | - | 1件: 13 13 |
2000 | Tecfidera (BG00012) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2001 | Tecfidera (BG12) | - | - | - | - | 1件: 13 13 |
2002 | TECFIDERA - 240 MG - CAPSULA RIGIDA GASTRORESISTENTE - USO ORALE - BLISTER (PVC/PE/PVDC-PVC ALLUMINIO) - 56 CAPSULE | - | - | - | - | 1件: 13 13 |
2003 | Tecfidera® | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2004 | Tecfidera® 120 mg | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2005 | Tecfidera® 120mg magensaftresistente Hartkapseln | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2006 | Tecfidera® 240 mg | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2007 | Tecfidera® 240mg magensaftresistente Hartkapseln | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2008 | Tecifdera (dimethyl fumarate) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
2009 | TEMELIMAB | 1件: Temelimab Temelimab | - | - | - | 1件: 13 13 |
2010 | Temelimab 18 mg/kg | 1件: Temelimab Temelimab | - | - | - | 1件: 13 13 |
2011 | Temelimab 36 mg/kg | 1件: Temelimab Temelimab | - | - | - | 1件: 13 13 |
2012 | Temelimab 36mg/kg | 1件: Temelimab Temelimab | - | - | - | 1件: 13 13 |
2013 | Temelimab 54 mg/kg | 1件: Temelimab Temelimab | - | - | - | 1件: 13 13 |
2014 | Temsirolimus | 1件: Temsirolimus Temsirolimus | 1件: D06068
D06068
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 4件: 13 13, 34, 89, 331 |
2015 | Temsirolimus Tablets | 1件: Temsirolimus Temsirolimus | 1件: D06068
D06068
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 13 13 |
2016 | Tenofovir | 1件: Tenofovir disoproxil Tenofovir disoproxil | 1件: D01982
D01982
| - | - | 6件: 2 2, 13, 25, 93, 265, 325 |
2017 | Tenofovir alafenamide | 2件: Tenofovir Tenofovir, Tenofovir alafenamide | 2件: D06074
D06074
,
D10428
| - | - | 2件: 2 2, 13 |
2018 | TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY] | 2件: Tenofovir Tenofovir, Tenofovir alafenamide | 2件: D06074
D06074
,
D10428
| - | - | 1件: 13 13 |
2019 | TERIFLUNOMIDE | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 3件: 13 13, 25, 26 |
2020 | Teriflunomide (HMR1726) | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
2021 | Teriflunomide 14 MG | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
2022 | Teriflunomide 14 MG Oral Tablet [Aubagio] | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
2023 | Teriflunomide capsule | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
2024 | TERIFLUNOMIDE HMR1726 | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
2025 | Testosterone | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 9件: 1 1, 2, 3, 13, 60, 76, 78, 113, 265 |
2026 | Testosterone undecanoate | 2件: Testosterone Testosterone, Testosterone undecanoate | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 13 13, 60 |
2027 | Tetanus diphtheria toxoid vaccine (Td) | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
2028 | Tetanus diphtheria toxoids vaccine | - | - | - | - | 1件: 13 13 |
2029 | Tetanus toxoid | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 4件: 13 13, 14, 46, 50 |
2030 | Tetanus toxoid (TT) containing vaccine (Td, Tdap) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
2031 | Tetanus toxoid vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 |
2032 | Tetanus, diphtheria, and acellular pertussis vaccine | 1件: Pertussis vaccine Pertussis vaccine | 1件: D06514
D06514
| - | - | 1件: 13 13 |
2033 | Tetracycline | 1件: Tetracycline Tetracycline | 1件: D00201
D00201
| - | - | 4件: 13 13, 46, 53, 97 |
2034 | Tetracycline - Statin - Antimycotic | 1件: Tetracycline Tetracycline | 1件: D00201
D00201
| - | - | 1件: 13 13 |
2035 | Tetrahydrocannabinol | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 4件: 8 8, 13, 36, 298 |
2036 | Tetrahydrocannabinol (THC) | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
2037 | TETRAHYDROCANNABINOL Botanical Drug Substance (THC BDS) | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
2038 | TG | - | - | - | - | 2件: 13 13, 37 |
2039 | TG-1101 | - | - | - | - | 1件: 13 13 |
2040 | THC | - | - | - | - | 5件: 8 8, 13, 36, 46, 96 |
2041 | Thiamine | 1件: Thiamine Thiamine | 1件: D08580
D08580
| - | - | 4件: 8 8, 13, 93, 265 |
2042 | THIOPLEX | - | - | - | - | 1件: 13 13 |
2043 | Thiotepa | 1件: Thiotepa Thiotepa | 1件: D00583
D00583
| - | - | 12件: 13 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284, 285 |
2044 | THYMOGLOBULINE | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 5件: 13 13, 36, 51, 60, 96 |
2045 | Thymoglobuline® | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 1件: 13 13 |
2046 | Thymol | 1件: Thymol Thymol | 1件: D01039
D01039
| - | - | 1件: 13 13 |
2047 | Tissue Selective Estrogen Complex | - | - | - | - | 1件: 13 13 |
2048 | Tizanidine | 1件: Tizanidine Tizanidine | 2件: D00776
D00776
,
D08611
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2049 | Tizanidine (sublingual or oral) | 1件: Tizanidine Tizanidine | 2件: D00776
D00776
,
D08611
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2050 | Tizanidine hydrochloride capsule | 1件: Tizanidine Tizanidine | 2件: D00776
D00776
,
D08611
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2051 | TMP001 | - | - | - | - | 1件: 13 13 |
2052 | Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
2053 | Tocilizumab Injection | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
2054 | Tocopherol | 1件: Tocopherol Tocopherol | 1件: D02332
D02332
| - | - | 5件: 13 13, 49, 206, 257, 298 |
2055 | Tolebrutinib | - | - | - | - | 2件: 11 11, 13 |
2056 | Tolebrutinib 120mg | - | - | - | - | 1件: 13 13 |
2057 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 |
2058 | Tolerogenic dendritic cells (tolDC) | - | - | - | - | 1件: 13 13 |
2059 | Tolerogenic Dendritic cells loaded with myelin peptides | - | - | - | - | 1件: 13 13 |
2060 | Tolerogenic Fibroblasts | - | - | - | - | 1件: 13 13 |
2061 | Tolperisone | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
| - | - | 1件: 13 13 |
2062 | Tolperisone HC1 | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
| - | - | 1件: 13 13 |
2063 | Tolperisone HCl | 1件: Tolperisone Tolperisone | 1件: D08617
D08617
| - | - | 1件: 13 13 |
2064 | Tolpersan | - | - | - | - | 1件: 13 13 |
2065 | Tolposan | - | - | - | - | 1件: 13 13 |
2066 | Topical Preparation H arm | - | - | - | - | 1件: 13 13 |
2067 | Torvast | - | - | - | - | 1件: 13 13 |
2068 | TORVAST*10CPR 10MG | - | - | - | - | 1件: 13 13 |
2069 | Tovaxin | - | - | - | - | 1件: 13 13 |
2070 | Tovaxin Autologous T Cell Vaccine | - | - | - | - | 1件: 13 13 |
2071 | Tracleer | 1件: Bosentan Bosentan | 2件: D01227
D01227
,
D07538
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 8件: 13 13, 51, 84, 85, 86, 88, 210, 211 |
2072 | Trancopal | - | - | - | - | 1件: 13 13 |
2073 | Trancopal Dolo | - | - | - | - | 1件: 13 13 |
2074 | Transcranial Magnetic Stimulation (TMS) | - | - | - | - | 1件: 13 13 |
2075 | Trekking pole (TP). | - | - | - | - | 1件: 13 13 |
2076 | TREOSULFAN | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 6件: 13 13, 19, 62, 65, 283, 286 |
2077 | Trichuris suis eggs | - | - | - | - | 3件: 13 13, 96, 97 |
2078 | Trichuris suis Ova | - | - | - | - | 4件: 13 13, 46, 96, 97 |
2079 | Trichuris suis ova (eggs), embryonated, viable | - | - | - | - | 1件: 13 13 |
2080 | Trileptal | 1件: Oxcarbazepine Oxcarbazepine | 1件: D00533
D00533
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
2081 | Triomar™ (omega-3 fatty acids) | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 13 13 |
2082 | Trivalent seasonal influenza vaccine | - | - | - | - | 1件: 13 13 |
2083 | TRO19622 | 1件: TRO19622 TRO19622 | - | - | - | 3件: 2 2, 3, 13 |
2084 | Trulicity | 1件: Dulaglutide Dulaglutide | 1件: D09889
D09889
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
2085 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: D09889
D09889
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
2086 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: D09889
D09889
| 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 |
2087 | TSO | - | - | - | - | 3件: 13 13, 46, 97 |
2088 | TT Vaccine | - | - | - | - | 1件: 13 13 |
2089 | TV-5010 | - | - | - | - | 1件: 13 13 |
2090 | TV-5600 | - | - | - | - | 3件: 8 8, 13, 96 |
2091 | Tylenol Pill | - | - | - | - | 1件: 13 13 |
2092 | TYSABRI | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 3件: 13 13, 25, 63 |
2093 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2094 | TYSABRI 300 mg concentrate for solution for infusion | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2095 | TYSABRI 300 mg solution à diluer pour perfusion | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2096 | TYSABRI and AVONEX | 2件: Interferon beta-1a Interferon beta-1a, Natalizumab | 2件: D04554
D04554
,
D06886
| 3件: IFNAR1 IFNAR1, IFNAR2, ITGA4 💬 | 30件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, Epstein-Barr virus infection, Focal adhesion, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Regulation of actin cytoskeleton, Toll-like receptor signaling pathway, Yersinia infection 💬 | 1件: 13 13 |
2097 | Tysabri ® (Natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2098 | TYSABRI*IV 1FL 300MG 15ML | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2099 | TYSABRI® | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2100 | Tysabri® (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
2101 | UBLITUXIMAB | 1件: Ublituximab Ublituximab | 1件: D11243
D11243
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
2102 | Ubltuximab | - | - | - | - | 1件: 13 13 |
2103 | Ucb L059 | - | - | - | - | 1件: 13 13 |
2104 | UK: Sativex Oromucosal Spray | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
2105 | Ultomiris | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 6件: 2 2, 11, 13, 50, 62, 66 |
2106 | Ultra small particles of iron oxide (USPIO) | 1件: Ferric oxide Ferric oxide | 1件: D04168
D04168
| - | - | 1件: 13 13 |
2107 | Ultrasmall particles of iron oxide | 1件: Ferric oxide Ferric oxide | 1件: D04168
D04168
| - | - | 1件: 13 13 |
2108 | Ultromiris | - | - | - | - | 1件: 13 13 |
2109 | Umbilical cord derived Mesenchymal Stem Cells | - | - | - | - | 1件: 13 13 |
2110 | Umbilical cord mesenchymal stem cells | - | - | - | - | 5件: 13 13, 46, 57, 97, 113 |
2111 | UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS | - | - | - | - | 1件: 13 13 |
2112 | Untreated to atorvastatin treatment | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
2113 | Urbason | - | - | - | - | 3件: 13 13, 97, 222 |
2114 | Urbason 40 mg | - | - | - | - | 1件: 13 13 |
2115 | URBASON 40 mg comprimidos | - | - | - | - | 1件: 13 13 |
2116 | URBASON FORTE | - | - | - | - | 1件: 13 13 |
2117 | Urbason solubile forte 1000mg | - | - | - | - | 1件: 13 13 |
2118 | Urbason® solubile forte 1000 mg | - | - | - | - | 1件: 13 13 |
2119 | Urine samples | - | - | - | - | 1件: 13 13 |
2120 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 |
2121 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 |
2122 | V08CA02 | - | - | - | - | 1件: 13 13 |
2123 | V08CA09 | - | - | - | - | 1件: 13 13 |
2124 | Vaginal estriol | 1件: Estriol Estriol | 2件: D00185
D00185
,
D01986
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 13 13 |
2125 | Vardenafil | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 3件: 13 13, 86, 299 |
2126 | Vardenafil (hidrocloride) | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2127 | Vardenafilo | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2128 | VARDENAFILO HIDROCLORURO | 1件: Vardenafil Vardenafil | 3件: D02731
D02731
,
D03260
,
D08668
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
2129 | Vatelizumab | 1件: Vatelizumab Vatelizumab | - | - | - | 2件: 13 13, 97 |
2130 | VAY736 | - | - | - | - | 7件: 13 13, 35, 46, 49, 53, 85, 95 |
2131 | VB13S1 | - | - | - | - | 1件: 13 13 |
2132 | VB5S2 | - | - | - | - | 1件: 13 13 |
2133 | VB6S5 | - | - | - | - | 1件: 13 13 |
2134 | Vehicle Gel | - | - | - | - | 2件: 13 13, 34 |
2135 | Venlafaxin Hexal | - | - | - | - | 1件: 13 13 |
2136 | Venlafaxine | 1件: Venlafaxine Venlafaxine | 2件: D00821
D00821
,
D08670
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 3件: 6 6, 13, 46 |
2137 | VENLAFAXINE HYDROCHLORIDE | 1件: Venlafaxine Venlafaxine | 2件: D00821
D00821
,
D08670
| 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 2件: 13 13, 46 |
2138 | Verum arm receiving Gilenya® | - | - | - | - | 1件: 13 13 |
2139 | Verum arm receiving Vitamin D oil | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 |
2140 | VESIcare 10Mg Tablet | - | - | - | - | 1件: 13 13 |
2141 | Vessel | - | - | - | - | 4件: 13 13, 51, 271, 288 |
2142 | Video calling program Better-close | - | - | - | - | 1件: 13 13 |
2143 | Video game therapy | - | - | - | - | 1件: 13 13 |
2144 | Vidofludimus | 1件: Vidofludimus Vidofludimus | - | - | - | 5件: 13 13, 46, 94, 96, 97 |
2145 | VIDOFLUDIMUS CALCIUM | 2件: Calcium Calcium, Vidofludimus | - | - | - | 4件: 13 13, 94, 96, 97 |
2146 | Vigantol | - | - | - | - | 4件: 13 13, 65, 96, 97 |
2147 | Vigantol Oel | - | - | - | - | 3件: 13 13, 96, 97 |
2148 | VIGANTOL OIL | - | - | - | - | 1件: 13 13 |
2149 | VigantOL oil plus interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
2150 | Vigantol® Oil | - | - | - | - | 1件: 13 13 |
2151 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 |
2152 | Vitamin A | 1件: Vitamin A Vitamin A | 2件: D00069
D00069
,
D06543
| 2件: RARA RARA, RARB 💬 | 8件: Acute myeloid leukemia Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 13 13, 53, 90 |
2153 | Vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 24件: 3 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299 |
2154 | Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 12件: 6 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299 |
2155 | Vitamin E | 1件: Vitamin E Vitamin E | 1件: D02331
D02331
| - | - | 11件: 2 2, 6, 13, 20, 46, 90, 96, 97, 206, 299, 317 |
2156 | Vitamin E/Selenium | 2件: Selenium Selenium, Vitamin E | 1件: D02331
D02331
| - | - | 1件: 13 13 |
2157 | Vitamin K | 1件: Phylloquinone Phylloquinone | 1件: D00148
D00148
| - | - | 5件: 13 13, 46, 96, 97, 299 |
2158 | VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA | - | - | - | - | 1件: 13 13 |
2159 | VSN16R | - | - | - | - | 1件: 13 13 |
2160 | VSN16R 100mg | - | - | - | - | 1件: 13 13 |
2161 | VX15/2503 | - | - | - | - | 2件: 8 8, 13 |
2162 | Warfarin | 1件: Warfarin Warfarin | 3件: D00564
D00564
,
D01280
,
D08682
| 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 13件: 6 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97 |
2163 | Warm compress prior to injection of glatiramer acetate | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
2164 | Water | 1件: Water Water | 1件: D00001
D00001
| - | - | 23件: 2 2, 5, 6, 13, 17, 19, 22, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 |
2165 | WAY-130799 | - | - | - | - | 1件: 13 13 |
2166 | Wristband physical activity monitor | 1件: Methamidophos Methamidophos | - | - | - | 1件: 13 13 |
2167 | XBD173 | - | - | - | - | 1件: 13 13 |
2168 | XCEL-MC-ALPHA | - | - | - | - | 1件: 13 13 |
2169 | Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 7件: 5 5, 6, 7, 13, 15, 17, 113 |
2170 | Xyosted | 1件: Testosterone enanthate Testosterone enanthate | 1件: D00958
D00958
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
2171 | XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector | 1件: Testosterone enanthate Testosterone enanthate | 1件: D00958
D00958
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
2172 | Zenapax | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
2173 | Zeposia | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
2174 | Zinbryta | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
2175 | ZK 157046 | - | - | - | - | 1件: 13 13 |
2176 | ZOL446H | - | - | - | - | 1件: 13 13 |
2177 | Zoledronic acid | 1件: Zoledronic acid Zoledronic acid | 4件: D01968
D01968
,
D06378
,
D06379
,
D08689
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 12件: 5 5, 6, 13, 17, 46, 93, 95, 96, 270, 274, 299, 333 |
2178 | ZOLEDRONIC ACID MONOHYDRATE | 1件: Zoledronic acid Zoledronic acid | 4件: D01968
D01968
,
D06378
,
D06379
,
D08689
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |